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...The sixth age shifts
Into the lean and slipper’d pantaloon,
With spectacles on nose, and pouch on side,
His youthful hose well sav’d, a world too wide,
For his shrunk shank...
(Shakespeare, The Seven Ages of Man)
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Chapter 1
General introduction and outline of thesis





In developed countries, life expectancy is increasing and the elderly population is 
expanding rapidly. In the past 40 years the population of adults aged over 65 years 
has doubled to almost 2.6 million in 2011 in the Netherlands only (1). In this ageing 
society sarcopenia is an emerging problem. The term sarcopenia was coined in 1988 
to describe the ‘deficiency’ (penia) of ‘flesh’ (sarx) as is often observed in old age. 
Annual loss of muscle mass has been reported as 1 to 2 percent from the age of 50 
years onwards (2;3). While the loss of muscle mass seems to be accelerated in the 
presence of chronic disease, even in life-long trained athletes muscle mass is much 
lower in old as compared to young age (2).
The introduction of the term sarcopenia contributed to research aimed to understand 
the consequences. There is a growing body of evidence that low muscle mass at old 
age is associated with self-reported physical disability and physical performance (4-
6). The change of muscle mass is related to changes in muscle strength. However, to 
generate muscle strength other factors are important in addition to muscle mass, such 
as neural control, cognition, cardiovascular and joint function (7). Reduced muscle 
strength has been found to be associated with dependency in activities of daily 
living (8;9), cognitive decline (10-12), and mortality (13;14). Next to the generation 
of muscle strength, muscle tissue is an important reserve of body proteins and 
energy that can be used in extreme conditions of stress or malnutrition. Low muscle 
mass is associated with higher drug toxicity (15;16) and reduced insulin sensitivity 
(17). Because of the multiple functions of muscle tissue, biological aspects as well 
as functional and mechanical aspects can be considered as muscle related clinical 
outcome of interest when studying sarcopenia.
Despite increasing knowledge about the consequences of sarcopenia, there is no 
consensus on the definition of sarcopenia. Since the coining of the term sarcopenia, 
researchers have been searching for diagnostic criteria for sarcopenia. This has lead 
to the use of a variety of diagnostic criteria for sarcopenia. In general, currently used 
diagnostic criteria for sarcopenia can be divided into criteria based on (1) low muscle 
mass (4;6), (2) low muscle strength (18), and (3) low walking speed (19;20). Muscle 
mass can be further divided into relative muscle mass and absolute muscle mass 
(figure 1) (21). With currently used diagnostic criteria for sarcopenia, the reported 
prevalence of sarcopenia varies extremely between elderly cohorts ranging from 7 
to over 50% (22). It remains unknown whether this range can be explained by true 
differences between cohorts, or by the application of various diagnostic criteria to 
define sarcopenia in these cohorts.
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Figure 1. Hypothetical example of the distribution of fat and muscle mass in three different 
persons with equal height, for visualization of differences between relative and absolute 
muscle mass. Person A and B have the same amount of body mass with a different amount 
of muscle mass and fat mass. Person B has a higher absolute (kg) amount of muscle mass 
and also a higher relative (percentage) amount of muscle mass compared to person A. Person 
C has the same absolute amount of muscle mass as person B, but with a higher body mass. 














Currenty, clinical awareness of the signs and consequences of sarcopenia is lacking. 
To diagnose sarcopenia in clinical practice a clear definition for sarcopenia is needed. 
The aim of this thesis is to assess the implications of the use of different diagnostic 
criteria for sarcopenia, and to define the most accurate criteria for sarcopenia.
Outline of this thesis
In chapter two the literature is reviewed for current knowledge on sarcopenia, 
concerning the diagnostic criteria for sarcopenia, the pathophysiology of sarcopenia, 
and its clinical implications. Chapter three compares the chronology in the history of 
defining osteoporosis with sarcopenia. This comparison is used to detect milestones 
needed to define both age-related disease definitions, and missing milestones still 
needed to reach consensus on the definition of sarcopenia. In chapter four the impact 
of the use of different diagnostic criteria on the prevalence of sarcopenia is assessed. 
This chapter answers the question whether differences in the reported prevalence 
of sarcopenia can be explained by the use of different diagnostic criteria within 
one study cohort. In the following four chapters diagnostic criteria for sarcopenia 
are compared in their association with different aspects of muscle related clinical 
outcome. The diagnostic criteria that are compared comprise relative muscle mass, 
absolute muscle mass, muscle strength, and walking speed. The muscle related 
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outcome of interest is: physical performance tested with the Timed get Up and Go 
test (TUG) and walking speed in chapter five; measures of insulin resistance derived 
from an oral glucose tolerance test in chapter six; whole body bone mineral density 
in chapter seven; and standing balance in chapter eight. In chapter nine the key 
findings of this thesis are summarized with a reflection, and recommendations for 
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Chapter 2
Sarcopenie: Op weg naar klinische toepasbaarheid
AY Bijlsma, CGM Meskers, RGJ Westendorp, AB Maier




Sarcopenia is a term introduced to describe ‘low muscle mass’. There is no consensus 
definition for sarcopenia; a variety of criteria are being used to establish the diagnosis 
of ‘sarcopenia’. Depending on the criteria used, the prevalence of sarcopenia in 
elderly varies from 7 to over 50 percent. The presence of sarcopenia often remains 
unrecognized when the loss of muscle mass is replaced by fat and connective tissue; 
body weight thus remains stable or even increases. Sarcopenia can be detected 
by measuring muscle mass with dual-energy X-ray absorptiometry (DXA) or 
bioimpedance analysis (BIA). Besides the generation of strength, muscle tissue is an 
important internal organ involved in protein storage, glucose regulation, hormonal 
homeostasis and cellular communication. Systemic, cellular, neuromechanical 
factors and lifestyle are linked to the pathophysiology of sarcopenia. Sarcopenia is 
associated with higher mortality, dependency in activities of daily living, toxicity of 
chemotherapy, and disturbed glucose regulation. 
Dutch abstract
Sarcopenie is geïntroduceerd als term voor ‘lage spiermassa’. Er is geen eenduidige 
definitie van sarcopenie. Er wordt een verscheidenheid aan criteria gebruikt om de 
diagnose ´sarcopenie´ te stellen. Afhankelijk van de gehanteerde definitie worden 
prevalentiecijfers van 7 tot meer dan 50 procent bij ouderen gerapporteerd. Sarcopenie 
blijft vaak onopgemerkt als de afnemende spiermassa wordt opgevuld door vet 
en bindweefsel; het gewicht blijft hierbij gelijk of neemt zelfs toe. Spiermassa kan 
worden gemeten met ‘dual-energy X-ray’ absorptiometrie (DEXA) of bio-elektrische 
impedantie-analyse (BIA). Spierweefsel is behalve krachtsleverancier ook als 
intern orgaan betrokken bij eiwitopslag, glucoseregulatie, hormoonhuishouding 
en cellulaire communicatie. Bij de pathofysiologie van sarcopenie zijn systemische, 
cellulaire en neuromechanische factoren en leefstijl betrokken. Sarcopenie houdt 
verband met een hogere sterfte, afhankelijkheid in dagelijks functioneren, toxiciteit 
van chemotherapie en verslechterde regulatie van de glucoseconcentratie. 




In onze vergrijzende samenleving is sarcopenie een veelvoorkomende maar voor 
velen onbekende aandoening. De term ‘sarcopenie’ is in 1988 geïntroduceerd om het 
verlies van spiermassa op oudere leeftijd te beschrijven (1). Dit woord is afgeleid van 
de Griekse woorden ‘sarx’ (vlees) en ‘penia’ (behoeftigheid).
Uit observationele studies is gebleken dat spiermassa tot het 30e levensjaar wordt 
opgebouwd en na een plateaufase afneemt met de leeftijd. Geschat wordt, dat na 
het 50e levensjaar de spiermassa ongeveer met 1 á 2 procent per jaar afneemt (2). Een 
vergelijkbaar beloop wordt gezien voor de spierkracht. De gemiddelde spierkracht 
bij 80-jarigen is bijna de helft van de spierkracht op jonge leeftijd, zo bleek uit cross-
sectionele studies (figuur 1) (3). Ziekte en immobiliteit kunnen dit proces versnellen, 
maar de spiermassa neemt ook af bij mensen die hun hele leven lichamelijk zeer 
Figuur 1: Het verband tussen spierkracht en leeftijd, weergegeven in een strooidiagram van 
330 studies onder de algemene bevolking; rond de meta-regressielijn is het 95%-betrouw-
baarheidsinterval met onderbroken lijnen aangegeven (gestandaardiseerd op 50% vrouwen). 
De handknijpkracht in de algemene bevolking is lager bij ouderen, met een omslagpunt op de 
leeftijd van 50 jaar (figuur afkomstig uit eerdere publicatie) (3).


























actief zijn geweest (2). 
De klinische relevantie van sarcopenie betreft niet alleen het fysieke functioneren door 
het genereren van kracht, maar ook de rol van spieren als intern orgaan dat betrokken 
is bij de glucoseregulatie en productie van energie en dat als lichaamsreserve dient 
voor eiwitten (2). Voordat de diagnose ‘sarcopenie’ in de klinische praktijk toegepast 
kan worden is een goede definitie noodzakelijk. Voor het vormen van een goede 
definitie is kennis over de betekenis van sarcopenie en inzicht in de pathofysiologie 
noodzakelijk. In dit artikel bespreken wij het huidig gebruik van verschillende 
definities van sarcopenie, het onderscheid tussen sarcopenie, kwetsbaarheid (‘frailty’) 
en cachexie, de pathofysiologie en tot slot de klinische relevantie van sarcopenie.
Definitie van sarcopenie
De afname van spiermassa is een geleidelijk proces. Het verlies van spiermassa 
blijft vaak onopgemerkt indien het gewicht hetzelfde blijft of toeneemt. De 
afnemende spiermassa wordt doorgaans opgevuld door weefsel zonder contractiele 
eigenschappen zoals vet en bindweefsel (in de spier en rond de spier). Derhalve is de 
body mass index (BMI) in deze gevallen geen betrouwbare maat om de hoeveelheid 
spiermassa vast te stellen. De spiermassa kan in de klinische praktijk eenvoudig 
gemeten worden met ‘dual-energy X-ray’ absorptiometrie (DEXA) of bio-impedantie 
(BIA) (4). Voor een afspiegeling van de spierkracht kan een handknijpkrachtmeter 
worden gebruikt (3). 
Tot op heden is er nog geen WHO-classificatie voor sarcopenie. In de literatuur wordt 
de term ‘sarcopenie’ gebruikt voor verschillende parameters: een lage spiermassa, 
een lage spierkracht, een lage loopsnelheid of een combinatie van deze factoren, met 
toepassing van verschillende correctiefactoren, zoals gewicht of lengte. De betekenis 
van deze term is dus niet altijd direct duidelijk.  De Tabel geeft de gehanteerde 
formules en afkappunten voor het stellen van de diagnose sarcopenie weer (5). 
Om de discussie rond de definitie van sarcopenie te stimuleren en consensus te 
bereiken zijn er internationale werkgroepen voor sarcopenie opgericht. Momenteel 
wordt voorgesteld sarcopenie als combinatie van een lage spiermassa en een 
lage loopsnelheid of knijpkracht te definiëren (6;7). Hier vallen echter kritische 
kanttekeningen bij te plaatsen. Gebruik van afgeleide factoren van spiermassa, 
namelijk spierkracht en loopsnelheid, maakt het onderscheid tussen sarcopenie 
en kwetsbaarheid (‘frailty’) moeilijk. Spierkracht en loopsnelheid worden naast 
spiereigenschappen ook bepaald door andere factoren zoals neurale aansturing, 
cardiovasculair functioneren, motivatie en pijn.
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Het toepassen van verschillende definities voor sarcopenie, met verschillende 
afkappunten en correctiefactoren, leidt tot een sterke variatie in prevalentiecijfers: 
bij ouderen boven de 60 jaar worden prevalenties van 7 tot 40 procent gemeld, tot 
meer dan 50 procent bij ouderen boven de 80 jaar (5;8). 
Sarcopenie in relatie tot kwetsbaarheid en cachexie
Sarcopenie wordt onderscheiden van cachexie en kwetsbaarheid. ‘Cachexie’ wordt 
gekenmerkt door ‘wasting’; bepaalde ziektes gaan vaak gepaard met cachexie. Ook 
bij cachexie wordt spierweefsel afgebroken, wat betekent dat cachectische patiënten 
eveneens aan de voorwaarden voor sarcopenie voldoen. 
Kwetsbaarheid is een geriatrisch syndroom dat gekenmerkt wordt door 
achteruitgang in meerdere domeinen. Hierbij spelen fysieke, psychische en sociale 
factoren een belangrijke rol. Tot op heden is het niet gelukt een eenduidige definitie 
voor kwetsbaarheid te vormen. In de praktijk betekent dit dat er vele testen en 
Tabel: Voorbeelden van veel gebruikte formules en afkapwaarden om een lage 
spiermassa of lage spierkracht vast te stellen.
Eerste auteur 
(meetmethode)a




ALM/lengte2 7.26 kg/m2 5.45 kg/m2 2 SD onder het gemiddelde van 






31% 22% 2 SD onder het gemiddelde van 




SLM/ lengte2 8.50 kg/m2 6.75 kg/m2 ROC-curve analyse voor afkap-
waarden gerelateerd aan fysieke 
beperkingen in 4502 personen 
ouder dan 60 jaar oud.
Prado (29) Dwarsdoorsnede 
spiermassa
52.4 cm2/m2 38.5 cm2/
m2
0.30x(dwarsdoorsnede spiermas-
sa op L3)+6.06; Afkapwaarden 
gerelateerd aan mortaliteit(CT)
Lauretani (7) Handkrijpkracht 30.3 kg 19.3 kg ROC-curve voor afkapwaarden 
gerelateerd aan loopsnelheid 
minder dan 0.8 m/sec in 1030 per-
sonen tussen 20 en 102 jaar oud.
ALM=som van de vet-vrije wekedelen massa van alle ledematen; SLM=geschatte skeletspiermassa van 
het gehele lichaam; SD=standaarddeviatie; ROC-curve=receiver operating characteristics curve (deze laat 
het verband zien tussen de sensitiviteit en de specificiteit van een test); DEXA=dual-energy x-ray absorp-
tiometrie; BIA=bio-impedantie analyse. aDeze methoden zijn in de aangehaalde onderzoeken gebruikt 
om de afkapwaarden vast te stellen.
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definities ontwikkeld zijn om kwetsbaarheid te meten, waaronder loopsnelheid en 
handknijpkracht (9). 
Pathofysiologie van sarcopenie 
In de afgelopen was er een flinke toename van kennis over veranderingen in 
systemische, cellulaire, neuromechanische factoren en leefstijl die bijdragen aan de 
afname van spiermassa. Aangezien de meeste studies naar de pathofysiologie van 
sarcopenie nog kleinschalig en het veelal om cross-sectioneel onderzoek gaat, is 
causaliteit nog niet aangetoond. Wel zijn er veelbelovende verbanden ontdekt. Een 
overzicht van factoren die bijdragen aan het ontstaan van sarcopenie is schematisch 
weergegeven in figuur 2. Een aantal factoren wordt hieronder toegelicht.
Neuromechanische factoren
Een typische dwarsgestreepte skeletspier bestaat uit vele spiervezels die worden 
Figuur 2: Schematische weergave van factoren die bijdragen aan de pathofysiologie van 
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aangestuurd door een kleiner aantal motorneuronen. De hoeveelheid spierkracht 
die gegenereerd kan worden hangt af van het aantal parallel gelegen sarcomeren 
(ofwel het oppervlak van de dwarsdoorsnede van de spier), terwijl de snelheid van 
contractie afhangt van het aantal in serie gelegen sarcomeren (ofwel de vezellengte). 
De structuur en functie van spiervezels wordt aangetast door verlies van spinale 
motorneuronen, bijvoorbeeld door apoptose. Wanneer gedenerveerde spiervezels 
opnieuw geïnnerveerd worden door collaterale uitgroei (‘sprouting’) van nabij 
gelegen motoraxonen of motoreindplaten, ontstaan zeer grote motorunits. Dit is een 
mogelijke oorzaak van het verlies van fijne motoriek op oudere leeftijd (10). Ook 
zijn er aanwijzingen dat door  verlies van motorneuronen het aantal spiervezels 
vermindert (hypoplasie) en het volume van de overgebleven spiervezels afneemt 
(atrofie) (10). 
Systemische en cellulaire factoren 
Op hogere leeftijd worden gemiddeld hogere bloedspiegels gedetecteerd van 
ontstekingsmediatoren zoals interleukine-6 (IL-6), tumornecrosefactor-alpha (TNF-
α) en C-reactief proteïne (CRP). De twee- tot viervoudige verhoging van deze 
waarden op oudere leeftijd vergeleken met de waarden op jongere leeftijd duidt 
op een laaggradig chronisch systemisch ontstekingsproces. Deze geringe verhoging 
op oudere leeftijd is hiermee goed te onderscheiden van acute infectie, waarbij veel 
hogere waarden worden gevonden (11). In longitudinale studies is er een verband 
aangetoond tussen hoge bloedwaarden van deze ontstekingsmediatoren en verlies 
van spiermassa (12). 
De capaciteit van spierweefsel om te groeien of te herstellen van opgelopen schade 
hangt voor het grootste gedeelte af van satellietcellen, de myogene stamcellen. In 
spierweefsel van oudere personen worden aanzienlijk lagere aantallen satellietcellen 
aangetroffen dan in het spierweefsel van jongere personen (13). De proliferatieve 
capaciteit van satellietcellen is beperkt, net als die van andere delende celtypen in 
het lichaam (14). Als een satellietcel niet in staat is tot proliferatie kan de cel of in 
een senescente staat gaan, of in apoptose. Aangezien spieren bestaan uit veelkernige 
cellen, kan apoptose van een enkele myonucleus en het bijbehorende sarcoplasma 
optreden terwijl de spiervezel behouden blijft. Apoptose is hiermee, mits goed 
gereguleerd, een geschikt middel om beschadigd weefsel te verwijderen. Deze 
regulatie kan op hoge leeftijd verstoord zijn, bijvoorbeeld door het disfunctioneren 
van mitochondriën en door verhoogde concentraties van TNF-α (11). 
In tegenstelling tot bij apoptose, blijft bij cellulaire senescentie de niet-functionele cel 
aanwezig in het weefsel, waardoor accumulatie van senescente cellen optreedt. 
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Leefstijl en andere factoren
Lichamelijke inactiviteit zorgt voor atrofie van de spier en hierdoor uiteindelijk tot 
functionele beperkingen. Functionele beperkingen leiden echter ook tot inactiviteit, 
waardoor wederom spiermassa verloren gaat en een negatieve spiraal ontstaat. De 
mate van inactiviteit wordt in de klinische praktijk vaak onderschat bij gebruik van 
(gevalideerde) vragenlijsten. Met bewegingsmonitors kan daadwerkelijke activiteit 
in de thuissituatie gemeten worden gedurende meerdere dagen. Op deze manier 
kan de invloed van dagelijkse bewegingspatronen op het ontstaan van sarcopenie 
worden opgehelderd. 
Ook andere leefstijlfactoren zoals dieet, zonexpositie en intoxicaties kunnen invloed 
hebben op het ontstaan van sarcopenie. De voedingstoestand speelt hierbij een zeer 
belangrijke rol. Uit studies naar dagelijkse eiwitinname bij ouderen blijkt dat een 
eiwitrijk dieet geassocieerd is met een hogere spiermassa (15). Door verminderde 
voedselinname, verminderde zonexpositie en verminderde capaciteit om vitamine 
D3 te synthetiseren, kan vitamine D-deficiëntie ontstaan, wat ook gepaard gaat met 
een verhoogd risico op sarcopenie (15).
Klinische relevantie van sarcopenie
Uit observationeel onderzoek is gebleken dat spiermassa een voorspeller is van 
klinisch zeer relevante uitkomstmaten zoals fysiek functioneren, ADL (activiteit 
dagelijks leven)-afhankelijkheid (8;16;17), het vermogen om te herstellen van 
operaties (18;19), en mortaliteit (20). 
Klinische relevant is ook de spier als belangrijke speler in cellulaire en mechanische 
interactie met omliggende weefsels, zoals vet en bot. Zo speelt spiermassa een rol 
bij het ontstaan van osteoporose, aangezien mechanische stimulatie door spieren de 
aanmaak van bot via osteocyten bevordert (21). Tevens is spierweefsel belangrijk 
voor glucoseregulatie, aangezien het grootste deel van de insulinegestimuleerde 
opname van glucose in spierweefsel plaatsvindt. 
Spiermassa en (geriatrische) oncologie
De spiermassa van een individu kan directe klinische consequenties hebben. 
Een voorbeeld hiervan zien we bij de dosering van chemotherapeutica. Het 
verdelingsvolume van medicijnen hangt significant af van de lichaamssamenstelling. 
Chemotherapeutica worden vaak op basis de body surface area (BSA) gedoseerd, 
waarbij geen rekening met spiermassa wordt gehouden. 
Wij deden een literatuurstudie naar de toxiciteit van chemotherapie en spiermassa 
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(Figuur 3). De geïncludeerde artikelen betroffen grotendeels kleine studies met 
minder dan 55 patiënten. In drie studies werd een positief verband tussen een lage 
spiermassa en toxische verschijnselen die dosisreductie noodzakelijk maakten (22-
24). In twee studies werd geen significante relatie gevonden tussen enerzijds een lage 
spiermassa en anderzijds het wel of niet afmaken van neoadjuvante chemotherapie 
(25) of toxiciteit bij hepatisch arterieel toegediende chemotherapeutica (26). In twee 
studies wordt niet direct het verband tussen spiermassa en toxiciteit beschreven, 
maar wel de waarneming dat de toediening van chemotherapie gepaard gaat met 
verlies van spiermassa (27;28), en met een nog sterkere afname van spiermassa als 
er al sprake was van een lage spiermassa voordat de chemotherapie was gestart 
(28). Op oudere leeftijd bleek er een slechte correllatie tussen de spiermassa en 
het lichaamsoppervlak (29). Dit betekent dat als men doseert op basis van het 
lichaamsoppervlak, patiënten met een zeer lage spiermassa een hogere dosis krijgen 
per kilogram spiermassa dan patiënten met een hoge spiermassa. 
Figuur 3: Schematische weergave van een literatuurstudie naar sarcopenie als risicofactor 
voor toxiciteit van chemotherapie bij bestaande maligniteit. Wij gebruikte hiervoor de volgen-
de zoekstrategie: (“Sarcopenia”[Mesh] AND “Neoplasms”[Mesh]) OR (“sarcopenia”[All 
Fields] AND (“neoplasm”[All Fields] OR “malignancy”[All Fields] OR “cancer”[All 
Fields])) AND (“1989/01/01”[PDAT] : “2012/11/15”[PDAT]).
124 artikelen geïdentificeerd in PubMed
90 artikelen geëxcludeerd
82 geen origineel onderzoek
8 dierstudies
34 artikelen beoordeeld op titel en abstract
14 artikelen geëxludeerd
2 niet over sarcopenie
4 niet over maligniteit
6 beschrijvend
2 interventie
8 artikelen geïncludeerd over toxiciteit
12 artikelen geëxcludeerd
9  over mortaliteit, niet over toxiciteit
3  over morbiditeit, niet over toxiciteit




De term sarcopenie beschrijft een lage spiermassa op oudere leeftijd. Een lage 
spiermassa blijft vaak onopgemerkt als de BMI gelijk is gebleven of zelfs is 
toegenomen. Sarcopenie gaat gepaard met fysieke beperkingen, morbiditeit en 
toegenomen mortaliteit. Recent onderzoek biedt meer inzicht in de pathofysiologie 
en klinische relevantie van sarcopenie. Consensus over een goede definitie van 
sarcopenie is wenselijk om de  toepassing van dit begrip in de klinische praktijk te 
bevorderen.
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Low muscle mass at older age has been associated with functional impairments, 
cognitive decline and mortality. The term sarcopenia, coined in 1988, has been used 
interchangeably to describe low muscle mass, strength, and function. Without a well 
defined definition, results of studies using the term sarcopenia cannot be compared. 
Difficulties in defining sarcopenia parallel the history of defining osteoporosis. To 
understand critical steps that are needed to reach consensus in defining age-related 
diseases, we have identified milestones in the history of defining osteoporosis and 
compared these to sarcopenia. As a result, the main missing steps in the process 
of defining sarcopenia are: specific treatment options, pharmaceutical interest, 
and public awareness. Similar to osteoporosis being defined as ‘low bone mineral 
density’, the term sarcopenia should be reserved for ‘low muscle mass’. Consensus 
must be reached regarding the diagnostic criteria to quantify muscle mass, correction 
factors, and reference populations used to define cut-off values of muscle mass.




Over the past decades, scientists have reached consensus on an exclusive definition 
of osteoporosis, which was instrumental in developing clinical protocols for early 
diagnosis and tailored treatment. Sarcopenia, a much younger term, was first used 
in 1988 to describe the deficiency of muscle tissue often observed in older age (1). 
The term sarcopenia is still largely unknown among clinicians and researchers. 
Identifying and treating sarcopenia is becoming increasingly important, since 
research has shown that low muscle mass is associated with functional and cognitive 
impairment (2-4) and increased mortality (5). After the age of 50 years, an average 
annual decline of 1 to 2 percent of muscle mass has been reported (6), leading to a 
50 percent reduction of muscle mass among those aged 80 years and older (3). It 
is estimated that a 10.5 reduction of the prevalence of sarcopenia could lead to a 
reduction of healthcare costs by 1.1 billion US dollars per year in the United States 
(7). However, the prevalence and measurable impact of sarcopenia depends crucially 
on how sarcopenia is defined. A proper definition is the necessary base for clinical 
diagnosis and development of tailored treatment. 
Over the past years the term sarcopenia has been used interchangeably to describe 
low muscle mass as well as low muscle strength and physical performance. Loss of 
muscle mass cannot fully explain loss of muscle strength and vice versa (8). While 
it has been proposed to define sarcopenia based on the presence of low muscle 
mass together with low muscle strength or function (9), it has also been suggested 
to restrict the term sarcopenia to low muscle mass and to use another term for 
low muscle strength: ‘dynapenia’ (10). The prevalence of sarcopenia in elderly 
populations was found to vary substantially (11;12). The use of various diagnostic 
criteria of sarcopenia is most likely to account for the differences. Consequently, 
difficulties arise when comparing different cohorts and individual patients (13).
The medical community did not agree on a definition of osteoporosis from its first 
medical interest in the early 1940s until the mid 1990s. The aim of this paper is to 
learn from the similarities and differences in defining sarcopenia with respect to 
osteoporosis. By identifying and comparing milestones in the process of decision 
making we aim to get insights into the required steps to be taken to reach a clinically 
applicable definition of sarcopenia. 
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Chronology of osteoporosis and sarcopenia
Milestones in the definition of osteoporosis
The term ‘osteoporosis’ (porous bone) was most probably launched by the French 
pathologist Lobstein ‘the Younger’ in 1830 (milestone 1: coining of a term, figure 
1). This term was derived from the Greek ‘osteon’ (bone) and ‘poros’ (little hole), 
and was initially used to describe cavities observed in human bone of his patients 
during autopsy (14). Though the term was widely accepted and described in medical 
dictionaries from that moment on, it was not until the 20th century that osteoporosis 
was considered a treatable disorder instead of an unavoidable condition just 
occurring with ageing. This was probably due to Albright and colleagues, who first 
made a medical definition for osteoporosis and described conditions associated 
with osteoporosis (milestone 2: understanding of consequences, figure 1). Since 
the presence of osteoporosis was mainly observed in postmenopausal women, 
treatment with estrogen was suggested (15) (milestone 3: available medication, 
figure 1). Albright defined osteoporosis as “too little formation of calcified bone”, 
with the bone itself being normally calcified, and exhibiting a normal rate of bone 
destruction (16;17).
After Albright’s definition, the interest of researchers in osteoporosis increased. 
However, researchers assigned different meanings to ‘osteoporosis’, with varying 
emphases on clinical, physiological, and biochemical factors. Until 1994, different 
definitions of osteoporosis were described in medical dictionaries (interchangeable 
use of the term osteoporosis, figure 1)(18). Furthermore, the definition of osteoporosis 
in Harrison’s ‘Principles of internal medicine’ varied over the years. In the Harrison 
of 1950, age was considered as one of the causal factors leading to atrophy of 
tissue. It was recognized that all tissues atrophy with age, and skeletal atrophy was 
termed osteoporosis (19). An age based distinction was made between ‘senile’ and 
‘postmenopausal’ osteoporosis. Women under the age of 65 years were diagnosed 
with postmenopausal osteoporosis; above 65 years of age they were diagnosed with 
senile osteoporosis (19-21). This definition was held until 1970, when osteoporosis 
was distinguished from ‘normal age-related bone loss’ and recognized as a disease 
(22). Age was considered the causal factor in ‘primary’ osteoporosis. If an underlying 
cause was identified such as immobilization, steroid use or gonadal insufficiency, it 
was called ‘secondary’ osteoporosis (22). Although there was no universal definition 
of osteoporosis, besides the estrogen therapy introduced by Albright, other drug 
therapies (e.g. bisphosphonates in 1960) were developed and introduced in patient 
care (23).

















































































































































































































































































































































































































































































































































































Before the introduction of dual-energy x-ray absorptiometry (DXA) scanners in 
1987, osteoporosis was diagnosed in a rather crude way, for example, when there 
was evidence of deformity of a vertebral body or fracture or other bone from minor 
trauma, or the bones were extensively demineralized, readily recognized on routine 
diagnostic x-ray films. Without the ability to detect osteoporosis in an early stage, 
osteoporosis was a disease with a sudden onset after a fracture in patients. Without 
a proper method to measure bone mineral density, no consensus was reached 
on how to define osteoporosis without the presence of fractures. In the 1980s, a 
massive public awareness campaign regarding osteoporosis was launched in the 
United States, largely funded by the pharmaceutical industry producing hormone 
replacement therapy and dairy industry promoting their products as bone-building 
treatments (milestone 4: pharmaceutical interest, figure 1) (18). The awareness was 
so widespread that by 1987, 85% of Americans knew what osteoporosis was, as 
compared to 15% in 1982 (milestone 5: public awareness, figure 1) (18). Investments 
were also made in imaging technology to measure bone-density in routine clinical 
practice, leading to the introduction of  the DXA scanners in 1987 (milestone 6: 
imaging) (24). Effort was made to define a reference standard against which a certain 
bone mineral density could be measured. Fracture risk was taken into account to 
define osteoporosis, to be able to start treatment before the onset of adverse events 
(milestone 7: criteria for quantification, figure 1) (25).
After the introduction of DXA, it was recognized that the clinically important cut-off 
points for bone mineral density varied according to a number of parameters such as 
sex, age, and racial origin (25;26). A definition was formulated at the WHO Consensus 
Conference of Osteoporosis in Copenhagen in 1990, where osteoporosis was defined 
‘a disease characterized by low bone mass, microarchitectural deterioration of bone 
tissue leading to enhanced bone fragility, and a consequent increase in fracture 
risk’ (27). In 1994 the World Health Organization (WHO) operationally defined 
osteoporosis as a bone density measured with DXA, 2.5 standard deviations (SD) 
below the mean for healthy women aged 20 – 29 years, also referred to as  a T-score 
of  -2.5 (milestone 8: WHO definition, figure 1) (28). These cut-off points, although 
arbitrarily defined based on sensitivity and specificity of the occurrence of fractures, 
are still being used today. 
Optimal risk assessment in osteoporosis still remains under debate in research. 
When the WHO diagnostic criteria were provided, the prevalence of osteoporosis 
was considered roughly equal whether assessed at the hip, lumbar spine or forearm 
(high degree of agreement between sites). However, with the introduction of new 
technologies (peripheral DXA, quantitative ultrasound, quantitative computed 
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tomography, and other radiographic techniques) applied to different skeletal sites 
of the body, it became clear that the same T-score from different skeletal sites and 
techniques yielded different information on the prevalence of osteoporosis and on 
fracture risk (29). Moreover, it has been recognized that using the same reference 
values for different races is far from optimal (29-31). After the introduction of a 
clinically applicable WHO definition of osteoporosis, other risk factors of fractures 
have been assessed to optimize the assessment of fracture risk in osteoporosis. The 
fracture risk depends not only on the bone mineral density but also on other factors 
like the level of being at risk for trauma (risk behavior or cognitive functioning), 
severity of the trauma, and underlying conditions such as rheumatoid arthritis (32). 
The Fracture Risk Assessment Tool (FRAX) was initiated and enables physicians 
to assess the 10-year probability of fracture for individual patients based on 
information about a patient’s clinical risk factors combined with a hip DXA scan 
(milestone 9: definition including risk stratification, figure 1) (32). While convenient 
in risk assessment, the definition of osteoporosis as defined by the WHO in 1994 
remained unchanged.
Milestones in the definition of sarcopenia
In 1988, Rosenberg coined the term ‘sarcopenia’ to describe ‘deficiency of muscle 
mass’ as a literal translation from Greek, where ‘sarx’ means ‘flesh’ and ‘penia’ means 
‘deficiency’ (milestone 1: coining of a term, figure 1) (1). Since the introduction of the 
term, the attention of the medical community to sarcopenia has grown. Nowadays 
the use of the term sarcopenia in literature has reached a level comparable to the use 
of the term osteoporosis 50 years ago (figure 2). 
For sarcopenia, the techniques to measure the amount of muscle mass were already 
in use at the time the term was coined, but there was little intention for application, 
since the clinical consequences were unknown. In 1998, Baumgartner et al. suggested 
a formula to define sarcopenia as appendicular lean mass (sum of lean mass of both 
arms and legs) divided by height squared. Values more than two standard deviations 
below the mean of a young reference population were classified as sarcopenia (3). 
Other researchers introduced different formulas to define sarcopenia using muscle 
mass corrected for a combination of height, fat mass, or total body mass (milestone 
7: criteria for quantification, figure 1) (4;33;34). 
The introduction of diagnostic criteria contributed to the understanding of the 
consequences of having low muscle mass. There is a growing body of evidence 
that muscle mass is associated with self-reported physical disability (3;4;35) and 
functional impairment (4;35) (milestone 2, understanding of consequences). 
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Figure 2: Amount of hits in the MEDLINE database with the term “osteoporosis” (white 
bars) and “sarcopenia” (black bars). Both terms were entered as a single term in the MED-
LINE database search engine per year with 5 year intervals.
Sarcopenia has also been defined by muscle strength represented by knee extension 
isometric torque or handgrip strength, lower extremity muscle power or physical 
performance such as gait speed (36) (milestone 7: criteria for quantification, figure 
1). It has also been proposed to define sarcopenia by combining muscle mass with 
muscle strength or function, such as a combination of low muscle mass with low gait 
speed (9;37;38). Interchangeable use of the term sarcopenia makes it impossible to 
compare studies on sarcopenia due to very little concordance between different used 
diagnostic criteria (13).
Reflection
We have identified milestones in the history of the definition of osteoporosis 
and compared these to milestones that have been reached for the definition of 
sarcopenia. Both disease definitions relate to chronological age and started with the 
identification, recognition, and branding of a phenomenon (milestone 1, coining 
of a term, figure 1). A relevant question is at what stage to consider the gradual 
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chronological ageing. In the past, the terms ‘disease’, ‘disorder’, and ‘condition’ have 
been used as synonyms in literature for osteoporosis, while they describe different 
phenomena. ‘Disease’ is a definite morbid process with characteristic symptoms, 
whereas a ‘disorder’ describes an abnormality of function and a ‘condition’ is a state 
or mode of being, especially a state of health (39). The severity and development of 
the process and the underlying pathophysiological process determines the term to 
be chosen. The detrimental outcome associated with sarcopenia justifies defining 
sarcopenia as a disease, comparable to osteoporosis (milestone 2: understanding of 
consequences, figure 1).
The difficulty in defining cut-off points for the amount of bone mineral density 
and muscle mass accounts for both osteoporosis and sarcopenia. Which reference 
populations should be used to decide whether the amount of muscle mass or bone 
mineral density is normal or abnormal? Concerning osteoporosis, cut-off points 
are based on the optimal combination of sensitivity and specificity to determine 
the occurrence of fractures. As in osteoporosis, for sarcopenia it is crucial to define 
reference groups, based on gender, ethnicity, and race. 
An important difference between osteoporosis and sarcopenia is a clearly defined 
clinical consequence, which is needed for evaluation of the diagnostic criteria and 
development of treatment. In case of osteoporosis the risk of fractures is used as 
clinical outcome parameter. For sarcopenia, a clear clinical outcome parameter 
is still lacking. It is undesirable to evaluate muscle quality in terms of physical 
performance and strength, since this is also dependent on other parameters such as 
the neural controller, cardiovascular fitness and joint function. Although the amount 
of muscle mass is associated with muscle strength (4;33;34;40), there is accumulating 
evidence that muscle mass and muscle strength are two different entities (10;41;42) 
and therefore the term ‘dynapenia’ was coined by Clark in 2008 to describe the loss 
of muscle strength occurring with age (10). Besides a generator of strength, muscle 
tissue is an important internal organ. Next to mechanical consequences, loss of 
muscle mass has physiological consequences. These include protein storage, glucose 
regulation, hormone production and other cellular mechanisms (6). Recent studies 
have shown that the ability to recover from life-threatening disease is dependent on 
a higher amount of muscle mass, as sarcopenia was associated with higher mortality 
rates after liver transplantation (43) and higher chemotoxicity, independent of 
confounding factors (44). This might also be of clinical relevance in determining 
whether or not a patient is suitable for organ transplantation or chemotherapy.
In conclusion, it appears that crucial milestones are missing in the development of a 
clinically applicable definition of sarcopenia. Obvious main lacking milestones are 
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the availability of specific drug therapy (and therewith pharmaceutical interest), 
public awareness of clearly defined disease consequences, and a universally accepted 
definition. Interchangeable use of the definition of sarcopenia makes it impossible 
to compare studies, to understand the pathophysiological process and to develop 
targeted therapies. Since muscle tissue is involved in multiple processes, we suggest 
defining sarcopenia as ‘low muscle mass’ without use of functional or metabolic 
outcome parameters. Consensus must be reached regarding reference values of the 
general population of different ethnicities and race and applied correction factors. 
Furthermore, proper outcome measures should be defined for valid risk assessment. 
Understanding of the underlying pathophysiological processes will lead to first 
treatment possibilities and introduction of the disease in clinical care. It is necessary 
to create public awareness and accelerate the process of reaching a universally 
accepted definition of sarcopenia. 
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Defining sarcopenia: the impact of different diagnostic 
criteria on the prevalence of sarcopenia in a large middle 
aged cohort
AY Bijlsma, CGM Meskers, CHY Ling, M Narici, SE Kurrle, ID Cameron, RGJ 
Westendorp, AB Maier




Sarcopenia, low muscle mass, is an increasing problem in our aging society. The 
prevalence of sarcopenia varies extremely between elderly cohorts ranging from 7 to 
over 50%. Without consensus on the definition of sarcopenia, a variety of diagnostic 
criteria are being used. We assessed the degree of agreement between seven 
different diagnostic criteria for sarcopenia based on muscle mass and handgrip 
strength, described in literature. In this cross-sectional study, we included men 
(n=325) and women (n=329) with complete measurements of handgrip strength 
and body composition values as measured by bioimpedance analysis within the 
Leiden Longevity Study. Prevalence of sarcopenia was stratified by gender and 
age. In men (mean age 64.5 years) the prevalence of sarcopenia with the different 
diagnostic criteria ranged from 0% to 20.8% in the lowest age category (below 60 
years), from 0% to 31.2% in the middle (60 to 69 years) and from 0% to 45.2% in 
the highest age category (above 70 years). In women (mean age 61.8 years) the 
prevalence of sarcopenia ranged from 0% to 15.6%, 0% to 21.8% and 0% to 25.8% 
in the lowest, middle and highest age category respectively. Only one participant 
(0.2%) was identified having sarcopenia according to all diagnostic criteria that 
marked prevalence above 0%. We conclude that the prevalence of sarcopenia 
is highly dependent on the applied diagnostic criteria. It is necessary to reach a 
consensus on the definition of sarcopenia in order to make studies comparable and 
for implementation in clinical care. 




Sarcopenia, low muscle mass at older age, is an increasing problem in our aging 
society. Annual loss of muscle mass has been reported as 1 to 2 percent at the age 
of 50 years onwards (1;2), and it exceeds over 50% among those aged 80 years and 
older when compared to younger adults (3). The change of muscle mass is closely 
related to changes in muscle strength. Reduced muscle strength has been found to 
be associated with dependency in activities of daily living (4;5), cognitive decline 
(6-8), and mortality (9;10). Next to the generation of muscle strength, muscle tissue 
is an important reserve of body proteins and energy that can be used in extreme 
conditions of stress or malnutrition. Low muscle mass is associated with higher 
drug toxicity (11;12) and reduced insulin sensitivity (13). 
Since the coining of the term ‘sarcopenia’ in 1989 by Rosenberg (14), many suggestions 
have been made to try to establish a clinically applicable definition. In general, three 
possible approaches in defining sarcopenia have been suggested. According to the 
first, the amount of muscle mass, measured with dual-energy x-ray absorptiometry 
(DXA) or bioimpedance analysis (BIA), compared to a younger reference population 
determines whether a person has sarcopenia. Correction factors applied using this 
approach are height (3;15), body mass (16), or both body height and body fat (17). 
In the second approach, muscle function is used as diagnostic criterion to define 
sarcopenia as compared to a younger reference population (18). The third approach 
combines both muscle mass and muscle function in the definition (19;20). 
Little is known about the degree of agreement between the diagnostic criteria and 
their effects on estimates of the prevalence of sarcopenia, which appears to vary 
extremely between different cohorts ranging from 7 to over 50% in the elderly (3;16-
18;21). The use of different diagnostic criteria may lead to different conclusions and 
may have different implications for treatment. To the best of our knowledge the 
differences in prevalence of sarcopenia in middle aged people comparing different 
diagnostic criteria has not been previously reported. In the present paper we 
explore the prevalence of sarcopenia using seven different diagnostic criteria in a 
large cohort of Dutch middle aged people. Furthermore, we assess the degree of 
concordance within individuals using the different criteria. Therewith, we aim to 
show the importance of reaching a consensus on the definition of sarcopenia, for 





The Leiden Longevity Study (LLS) consists of long-living Caucasian siblings of 420 
families together with their middle aged offspring, and the partners of the offspring 
as controls (22). The study included 674 participants of the middle aged to older 
offspring and their partners, who were assessed in the period from 2006 to 2008. 
The sample of partners in the study was representative of the Dutch population 
(22). Participants (n=20) with missing data for body composition measured with 
Direct Segmental Multi-frequency Bioelectrical Impedance Analysis (DSM-BIA) 
were excluded from the present analysis. There were no selection criteria on health 
or demographic characteristics (23). The Medical Ethics Committee of the Leiden 
University Medical Centre approved the study, and written informed consent was 
obtained from all participants.
Participant characteristics
At baseline, information on common chronic diseases and medication use was 
obtained from the participants’ general practitioner, pharmacist’s records, and 
from blood sample analyses. The chronic diseases recorded were diabetes mellitus, 
chronic obstructive pulmonary disease, malignancy, myocardial infarction, stroke, 
and hypertension. Health behaviour variables included current smoking status and 
excessive alcohol use (male > 210 g/week and female > 140 g/week).
Body composition
Body mass and body height were measured. DSM-BIA was performed using the 
In-Body (720) body composition analyser (Biospace Co., Ltd, Seoul, Korea). We have 
previously shown this technique to be a valid tool for the assessment of whole body 
composition and segmental lean mass measurements in our sample of a middle 
aged people (24). Excellent agreements were observed between the DSM-BIA 
technique and DXA in whole body lean mass (intraclass correlation coefficient (ICC) 
female=0.95, p<0.001, ICC male=0.96, p<0.001) and fat mass (ICC female 0.97 p<0.001, 
ICC male 0.93 p<0.001) (24). The DSM-BIA technique is based on the assumption 
that the human body is composed of 5 interconnecting cylinders and takes direct 
impedance measurements from the various body compartments. A tetrapolar eight 
point tactile electrode system is used, which separately measures impedance of 
the participant’s trunk, arms, and legs at six different frequencies (1 kHz, 5 kHz, 
50 kHz, 250 kHz, 500 kHz, and 1000 kHz) for each of the body segments. The 
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spectrum of electrical frequencies is used to predict the intracellular water (ICW) 
and extracellular water (ECW) compartments of the total body water (TBW) in the 
various body segments. Lean body mass is estimated as TBW (ICW + ECW)/0.73. 
Body fat mass is calculated as the difference between total body mass and lean mass. 
The machine gives immediate detailed results including quantitative values of total 
body and segmental lean mass, fat mass, and percentage fat mass. Appendicular 
lean mass (ALM) calculation was based on the sum of lean mass in all four limbs. 
Relative ALM was calculated as ALM divided by body height in meters squared (3). 
Participants wore normal indoor clothing and were asked to stand barefoot on the 
machine platform with their arms abducted and hands gripping on to the handle of 
the machine.
Handgrip strength
Handgrip strength was measured to the nearest kilogram using a Jamar hand 
dynamometer (Sammons Preston, Inc., Bolingbrook, IL, USA). All participants 
were instructed to maintain an upright standing position, arms down by the side, 
and holding the dynamometer in the dominant hand without squeezing the arm 
against the body. The width of the dynamometer’s handle was adjusted to the hand 
size of the participants such that the middle phalanx rested on the inner handle. 
Participants were allowed to perform one test trial, followed by three trials, and the 
best measurement was taken for analysis.
Diagnostic criteria of sarcopenia
An overview of different diagnostic criteria of sarcopenia (coded A to G) as described 
in the literature, which included muscle mass and handgrip strength is given in 
table 1 (3;15;16;18;25). Only diagnostic criteria based on measurements of muscle 
mass by BIA (definition E and F) or DXA (definition A, B, C, and D) scanning were 
used in this comparison. For each of these formulas, a different reference population 
had been used to derive a cut-off point for sarcopenia. For the formula ALM divided 
by height squared (definition A, B, and C), we found three different cut-off points for 
men and women, established in different reference populations (3;25;26). Reference 
populations were different in age and ethnicity, consisting of younger participants 
of the Rosetta study (definition A)(3), the NHANES survey (definition C)(26), and 
the NHANES III study (definition E)(16); elderly participants were included as 
reference population in the Health ABC study (definition B)(25), and the NHANES 
III study (definition F)(15); the whole adult age range was included in the reference 
population in the InCHIANTI study (definition G)(18). The formula described in 
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definition D, was applied to our cohort, using the 20th percentile as cut-off point for 
sarcopenia (25). Consequently, we used a total of seven different diagnostic criteria 
of sarcopenia in our analysis. 
Statistical analysis
Data were analysed for men and women separately. Because there was no significant 
difference in fat percentage, relative ALM, and handgrip strength between offspring 
and partners of the LLS, data for both groups were combined (27). The prevalence 
of sarcopenia in this population was assessed for all seven diagnostic criteria as 
described in table 1. For definition D, the residuals of linear regression of ALM with 
height and fat mass were calculated.
After assigning the status of sarcopenia being present or not present in the 
participants according to each of the seven diagnostic criteria, participants were 
stratified by gender and age. The lowest age category included participants aged 
below 60 years, the middle age category included participants aged 60 to 69 years 
and the highest included participants aged 70 years and above. Differences between 
age groups in characteristics were assessed with linear regression or binary logistic 
regression. The degree of concordance within individuals using the different 
diagnostic criteria of sarcopenia was assessed in all participants.
All statistical analyses were performed using SPSS for Windows (SPSS Inc, Chicago), 
version 17. P values <0.05 were considered statistically significant.
Results
Baseline characteristics of the study participants stratified by gender and age are 
presented in Table 2. Overall, the prevalence of comorbidity was slightly higher in 
older participants (statistically not significant). Skeletal lean mass as a percentage of 
body mass and grip strength were significantly lower in the older age groups. ALM 
divided by height squared was significantly different between the age groups in 
men, but not in women.
The prevalence of sarcopenia using the seven different diagnostic criteria is shown in 
Table 3. In men, the prevalence ranged from 0% to 20.8% in the lowest age category, 
from 0% to 31.2% in the middle age category and from 0% to 45.2% in the highest 
age category. In women, percentages ranged from 0% to 15.6%, 0% to 21.8% and 0% 
to 25.8% in the lowest, middle and highest age category respectively. 
Definitions A, B, and C are based on the same formula taking height into account, 
but each comprised different reference populations and strategies to define cut-
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off points. In men prevalence varied from 0% to 3.9% (lowest age category), 0% to 
4.3% (middle age category) and 0% to 6.5% (highest age category). In women this 
variation for definitions A, B, and C was 0% to 3.1% (lowest age category), 0% to 
3.5% (middle age category) and 0% (highest age category). When applying cut-off 
points for definition E class II, two men (0.6%) and 1 woman (0.3%) were classified as 
sarcopenic. The prevalence of sarcopenia was higher when applying cut-off points 
for definition E class I. Only one of the men (0.3%) was sarcopenic according to 
definition F class II criteria, based on muscle mass and height. The prevalence was 
higher using definition F class I criteria. The use of definition G which included 
handgrip strength gave a prevalence of less than 4% in this middle aged cohort.
Figure 1 shows the distribution of participants identified as sarcopenic according 
to the different diagnostic criteria. Definition C, which gave zero prevalence of 
sarcopenia is omitted. For definition E and F, class I and class II sarcopenia are 
combined. Out of the 654 participants, 436 did not have sarcopenia according to 
any definition. For 218 participants, the diagnosis of sarcopenia depended on the 
diagnostic criteria applied. Only one of the participants (0.2%) was sarcopenic 
according to all six definitions. 
Discussion
In this large middle aged Dutch cohort, the prevalence of sarcopenia varied widely 
depending on which diagnostic criteria were used. Criteria based on low grip 
strength and skeletal lean mass failed to match with criteria based on appendicular 
lean mass. There was substantial overlap between diagnostic criteria A and B which 
are both based on the amount of appendicular lean mass, yet another cut-off point 
for the amount of appendicular lean mass resulted in the absence of sarcopenia 
(diagnostic criterium C). These findings clearly demonstrate the highly different 
selection of participants with the diagnosis sarcopenia using various criteria. 
Consequently, there are concerns about the validity of comparisons between studies 
using different criteria to diagnose sarcopenia.
The question arises which properties of skeletal muscle are represented by the 
term sarcopenia. Besides the production of force, muscle tissue is also an important 
regulator of biological processes. For instance, as a protein store it provides a 
homeostatic reserve to recover from disease (28). Furthermore, skeletal muscle has 
been identified as the major tissue involved in glucose metabolism (29;30). Current 
evidence suggests that lean body mass may be a better measure for normalising 
dosages of drugs that are distributed and metabolised in lean tissue, compared 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































with body surface area alone (11;12;31). This underlines the importance to evaluate 
muscle mass in aging subjects.  
In the present study, there was little overlap between individuals with low grip 
strength and low muscle mass using the diagnostic criteria. A possible explanation 
is that muscle strength is not only determined by muscle mass. The amount of 
muscle mass represents the number of sarcomeres that are in parallel. As each 
sarcomere is capable of exerting an amount of force, the number of sarcomeres in 
parallel, together with the quality of proteins and connective tissue determines the 
amount of force that a muscle can potentially exert. Additionally, muscle function 
is dictated by energy supply and neural control. Consequently, the terms muscle 
mass and muscle strength cannot be used interchangeably (32). The rate of decline 
in muscle strength at older age appears to be higher than the decline in muscle mass 
in a 3-year longitudinal study, suggesting that factors other than muscle mass are 
influential (33). Additionally, the increase of strength after resistance training is 
higher than the increase in muscle mass in older adults (34-37). In a recent meta-
analysis it was shown that handgrip strength decreases each year with 0.37 kg (95% 
CI 0.31-0.44) after 50 years of age (38). Still, the low prevalence of sarcopenia in 
our cohort based on cut-off points for handgrip strength can possibly be explained 
by the fact that our cohort was middle aged and not over 80 years of age, where 
lower muscle strength becomes even more apparent (39). Recently a new term, 
dynapenia, has been developed to describe low muscle strength at old age (32). The 
use of the terms dynapenia for low muscle strength, and sarcopenia for low muscle 
Codea Men Women
<=59 y 60-69 y >=70 y Total <=59 y 60-69 y >=70 y Total
(n=77) (n=186) (n=62) (n=325) (n=128) (n=170) (n=31) (n=329)
A 3 (3.9) 8 (4.3) 4 (6.5) 15 (4.6) 2 (1.6) 5 (2.9) 0 7 (2.1)
B 3 (3.9) 8 (4.3) 4 (6.5) 15 (4.6) 4 (3.1) 6 (3.5) 0 10 (3.0)
C 0 0 0 0 0 0 0 0
D 12 (15.6) 35 (18.8) 18 (29.0) 65 (20.0) 20 (15.6) 37 (21.8) 8 (25.8) 65 (19.8)
E1 3 (3.9) 17 (9.1) 16 (25.8) 36 (11.1) 4 (3.1) 8 (4.7) 4 (12.9) 16 (4.9)
E2 1 (1.3) 0 1 (1.6) 2 (0.6) 0 0 1 (3.2) 1 (0.3)
F1 16 (20.8) 58 (31.2) 28 (45.2) 102 (31.4) 0 0 1 (3.2) 1 (0.3)
F2 0 0 1 (1.6) 1 (0.3) 0 0 0 0
G 1 (1.3) 2 (1.1) 5 (8.1) 8 (2.5) 3 (2.3) 6 (3.5) 0 9 (2.7)
Table 3: Prevalence of sarcopenia (n %) in the middle aged study population strati-
fied by gender and age.
aThe letters represent codes for the applied definition. The code is fully described in Table 1. 
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Figure 1: Number of participants identified as having sarcopenia according to various 
definitions, represented by letter codes. A description of the codes can be found in table 1. A 
total of 654 were evaluated. Definition C, in which no participants were sarcopenic, is not 
shown. In definition E and F, class I and II sarcopenia are combined. Two subjects, one in 
whom sarcopenia was diagnosed according to F, G and E, and one in whom sarcopenia was 
diagnosed according to B and D are not shown in the figure. 
mass, emphasises the differences between muscle strength and mass. However, this 
terminology might overcomplicate the situation unnecessarily, since muscle mass is 
also needed to generate strength. In other words, low muscle strength is one of the 
possible consequences of low muscle mass.
The prevalence of sarcopenia determined by diagnostic criteria using ALM 
corrected for height was not related to chronological age in women. However, the 
total lean mass as a percentage of total body mass was lower in all older subjects. 
This provides evidence that the interpretation of the amount of muscle mass is 
highly dependent on applied correction factors, such as fat mass and height. This 
is supported by Newman et al., who found that correction for height only could 
lead to an overestimation of sarcopenia in underweight individuals, compared to 
an underestimation of sarcopenia in obese individuals (17). Furthermore, recent 
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studies suggest that high fat mass is an important and independent determinant of 
functional status in elderly, even after adjustment for the level of physical activity 
(40-43). 
Next to a valid assessment of the amount of muscle mass, some variability emerges 
from the comparison to different reference populations and different cut-off points. 
Even with this variability, the degree of agreement between diagnostic criteria with 
the same formula but different cut-off points (definition A and B) was substantial. 
The prevalence of sarcopenia of zero percent using definition C can be explained 
by differences in reference populations. Furthermore, the prevalence of sarcopenia 
with definition A in this study cohort was much lower than reported in the same 
age categories by Baumgartner et al. (1998). In that study, using the same cut-off 
points in non-Hispanic whites, the prevalence of sarcopenia was found to be 13.5%-
23.1% below 70 years, and 19.8%-33.3% between 70-74 years, in men and women 
respectively. Differences in reference groups may be caused by age, ethnicity, 
genetic background, and environmental factors such as the level of physical activity. 
Therefore, it is important to agree on reference populations that can be used in 
specific ethnic groups. Establishing reference databases generally requires a large 
sample size to achieve reliable results. Reference databases established to diagnose 
osteoporosis could function as a role model. Furthermore, it remains important 
to invest in longitudinal studies including the general population assessing the 
relation between muscle mass and functional outcomes to establish possible critical 
thresholds of muscle mass needed for muscle function.  
Until now, attempts to approve on a consensus definition for sarcopenia failed. To 
the best of our knowledge, three international consortia have agreed on distinct 
definitions, which have not been generally accepted in the medical community. The 
first consensus definition was published by the Special Interest Groups (SIG) in 2009 
(20). Here, the diagnosis sarcopenia is based on a combination of low muscle mass as 
defined by Janssen in 2002 (definition E)(16), together with low gait speed, which is 
walking speed below 0.8 m/s in the 4-m walking test, or another functional test (20). 
The second consensus definition was published by The European Working Group 
on Sarcopenia in Older People (EWGSOP) in 2010. The EWGSOP included a degree 
of severity of sarcopenia in the definition. ‘Presarcopenia’ was defined as low muscle 
mass, ‘sarcopenia’ as low muscle mass together with either low muscle strength or 
performance and ‘severe sarcopenia’ as a combination of all three. In addition, it was 
proposed that sarcopenia should be considered ‘primary’ when no other cause is 
evident but aging itself, and ‘secondary’ when one or more other causes are evident 
(19). This terminology is not acceptable in modern gerontology, as age in itself is no 
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longer considered a causal factor of disease (44). In the third consensus definition, 
Fielding et al. based the diagnosis of sarcopenia on low muscle mass as defined by 
Delmonico et al. (definition B)(25), together with low gait speed defined as less than 
1 m/sec (45).
In our opinion, these consensus definitions are not clinically applicable. First of all, 
using the SIG definition none of the participants in the present study fulfilled the 
criteria for low muscle mass. Furthermore, gait speed is not a parameter of muscle 
function alone, but also dependent on other factors such as cognition, neural control, 
joint function, and cardiovascular fitness (46). The EWGSOP definition lists different 
ways to diagnose sarcopenia, without making a choice which measurement should 
be used. Consequently, the huge variability of prevalence of sarcopenia highlighted 
in the present study would therefore still be present. Defining sarcopenia based 
solely on the amount of muscle mass avoids all afore mentioned problems. 
The strength of the present study is that the currently used diagnostic criteria of 
sarcopenia were applied to one study population. Previously, we have shown an 
excellent correlation between BIA and DXA measurements (24); therefore we were 
able to apply diagnostic criteria based on both DXA and BIA measurements. A 
possible limitation of this study is selection bias of the participants, since only the 
partners of the offspring of nonagenarian siblings are considered to be representatives 
of the general population. However, the offspring of long-lived families did not 
differ significantly from their partners in fat percentage, muscle mass, and handgrip 
strength (27). Therefore, this would not influence conclusions made in the present 
study. Moreover, participants were middle aged; the degree of agreement between 
the different diagnostic criteria for sarcopenia might be different in an oldest old 
population. Another limitation is that we had no functional outcome measures 
available for participants in this study. We were not able to apply diagnostic criteria 
for sarcopenia based on gait speed. 
In conclusion, the prevalence of sarcopenia varies widely depending on the applied 
diagnostic criteria. A consensus definition is necessary in order to make studies 
comparable and for implementation in clinical care. We suggest defining sarcopenia 
as ‘low muscle mass’, to do justice to the multifunctionality of muscle tissue. ‘Low 
muscle mass’ can be diagnosed with DXA and BIA, while ‘loss of muscle mass with 
aging’ cannot be measured in an individual at one time point.  Further research 
should focus on establishing an appropriate formula to correct the amount of muscle 
mass for factors such as height and fat mass, and take into account differences in 
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Relative and absolute muscle mass and muscle strength are used as diagnostic criteria 
for sarcopenia. We aimed to assess which diagnostic criteria are most associated with 
physical performance in 180 young (18-30 years) and 281 healthy old participants 
(69-81 years) of the European study MYOAGE. Diagnostic criteria included relative 
muscle mass (total or appendicular lean mass (ALM) as percentage of body mass), 
absolute muscle mass (ALM/height2 and total lean mass), knee extension torque, and 
handgrip strength. Physical performance comprised walking speed, Timed Up and 
Go test (TUG), and in a subgroup physical fitness. Diagnostic criteria for sarcopenia 
and physical performance were standardized and the associations were analyzed 
using linear regression models stratified by age category, with adjustments for age, 
gender, and country. In old participants, relative muscle mass was associated with 
faster walking speed, faster TUG, and higher physical fitness (all p <0.001). Absolute 
muscle mass was not associated with physical performance. Knee extension torque 
and handgrip strength were associated with faster walking speed (both p≤0.003). 
Knee extension torque was associated with TUG (p=0.001). Knee extension torque and 
handgrip strength were not associated with physical fitness. In young participants, 
there were no significant associations between diagnostic criteria for sarcopenia 
and physical performance, except for a positive association between relative muscle 
mass and physical fitness (p<0.001). Relative muscle mass, defined as lean mass or 
ALM percentage, was most associated with physical performance. Absolute muscle 
mass including ALM/height2 was not associated with physical performance. This 
should be accounted for when defining sarcopenia.




Sarcopenia has been associated with self reported mobility limitations (1), cognitive 
decline (2), and mortality (3). The onset of age related loss of muscle mass occurs 
as early as 30 years of age, with a decrease of 1 to 2 percent after the age of 50 
years, and results in a loss of over 50 percent by the age of 80 years (1;4). During 
the last two decades, several diagnostic criteria for sarcopenia have been proposed, 
which can be categorized into measures of relative muscle mass (defined as total or 
appendicular lean mass (ALM) as percentage of body mass), absolute muscle mass 
(defined as appendicular lean mass (ALM) corrected for height (ALM/height2) or 
total lean mass), muscle strength, walking speed or a combination of criteria (5;6). 
Previously, we have shown that the prevalence of sarcopenia is highly dependent on 
the diagnostic criteria (7). 
Evidence-based consensus on the most clinically relevant diagnostic criteria for 
sarcopenia requires exploration of its association with muscle-related clinical 
outcome, such as physical performance. Relative muscle mass (lean mass percentage 
or ALM percentage) has been consistently associated with physical performance (8-
10). However, expressing muscle mass in a different way, such as the absolute muscle 
mass (ALM/height2), has led to conflicting results with some studies showing an 
association with self-reported mobility limitations and physical performance (1;10), 
and others finding no significant relationship between absolute muscle mass and 
physical performance (11-13). There are also mixed reports from studies relating 
muscle strength with physical performance. For instance, muscle strength was 
associated with self-reported mobility limitation (9;14), and physical performance 
(9;12), but this is not a consistent finding (13). There are no studies available that have 
explored these different indices of muscle mass and strength, with measurements of 
physical performance, in the same cohort.
We compared the association of different diagnostic criteria for sarcopenia (absolute 
and relative muscle mass, muscle strength) with physical performance, consisting of 
walking speed, Timed Up and Go test (TUG), and physical fitness as estimated with 
the Astrand fitness test in a group of young and old men and women participating 
in the MYOAGE study.
Methods
Study design 
MYOAGE is a cross-sectional European multicenter study of young (aged 18 to 
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30 years) and relatively healthy old participants (aged 69 to 81 years). A detailed 
description of the study design has been reported elsewhere (McPhee et al., 
submitted). Participants were recruited by focused advertisement in newspapers, 
third generation university, association of emeriti and universities, hereby selecting 
cognitively active individuals. In total, 461 participants were included: 110 recruited 
in Leiden, the Netherlands, 105 in Jyvaskyla, Finland, 100 in Tartu, Estonia, 62 in 
Paris, France and 84 in Manchester, United Kingdom. 
Exclusion criteria were aimed to ensure selection of healthy participants and 
minimize the confounding effect of comorbidity on sarcopenia. In short, exclusion 
criteria were: dependent living situation, inability to walk a distance of 250 m, 
presence of morbidity (neurologic disorders, metabolic diseases, rheumatic diseases, 
recent malignancy, heart failure, severe chronic obstructive pulmonary disease 
(COPD), haemocoagulative syndromes), use of medication (immunosuppressive 
drugs, insulin), immobilization for 1 week during the last 3 months, and orthopedic 
surgery during the last two years or still causing pain or functional limitation.
Measurements were performed according to unified standard operating procedures 
during visits to the local study centers. The local medical ethical committees of the 
respective institutions approved the study. Written informed consent was obtained 
from all participants.
Diagnostic criteria for sarcopenia
Muscle mass
A whole body scan was performed using Dual-energy X-ray absorptiometry (DXA) 
(Netherlands: Hologic QDR 4500, version 12.4, Hologic Inc., Bedford, USA; Finland: 
Lunar Prodigy, version EnCore 9.30; Estonia: Lunar Prodigy Advanced, version 
EnCore 10.51.006; France: Lunar Prodigy, version EnCore 12.30; United Kingdom: 
Lunar Prodigy Advance, version EnCore 10.50.086). Participants wore a light 
cotton shirt to reduce measurement errors due to clothing absorption. A trained 
technician performed the dual-energy X-ray absorptiometry. From the DXA, total 
and compartmental lean mass and fat mass were measured. Lean mass was used as 
an estimation of muscle mass.
To obtain relative muscle mass, lean mass percentage was calculated as lean mass 
divided by body mass in percentage (8), and appendicular lean mass (ALM) 
percentage as the sum of lean mass of both arms and legs divided by body mass in 
percentage (12). 
To obtain absolute muscle mass, ALM/height2 was calculated as ALM divided by 
height squared (1), and total lean mass was directly derived from DXA in kilograms.




Isometric knee extension torque was measured with a knee extension dynamometer 
chair (Netherlands: Forcelink B.V., Culemborg, the Netherlands; Finland: custom 
made; Estonia: custom made; France: Biodex system 3 Pro isokinetic dynamometer, 
Biodex Medical Systems, Shirley, New York, USA; UK: custom made). The 
participants were positioned in an upright position, with straps to fix the hips to the 
chair and the ankle to a force or torque transducer at the knee angle of 90 degrees. 
Lever arm length was recorded as the distance between the knee axis of rotation 
and the centre of the force transducer located at the point of force application above 
the malleoli. After three warm up trials at 50 % and 90 % of self-perceived maximal 
strength, three trials were conducted to measure maximal voluntary contraction 
(MVC) force of the knee extensor muscles. For each attempt, maximal force or torque 
was recorded. Each trial was separated by one minute of rest. Knee extension torque 
was obtained either directly or by multiplying recorded peak force with the lever 
arm length (in m). The trial with the highest torque output was selected for analyses.
Handgrip strength was measured using the Jamar handgrip dynamometer (Sammons 
Preston Inc, Bolingbrook, IL, USA). The width of the dynamometer was adjusted 
for each participant separately for optimal fit. Participants were instructed to stand 
upright with the dynamometer beside but not against their body. Measurements 
were performed three times for each side. The best of all attempts was used for 
further analysis. 
Physical performance
Walking speed was measured as the average speed during a six-minute walking 
test. Participants were instructed to walk around cones placed 20 meters apart (or 25 
meters in France). In Finland, Estonia, France, and UK participants were instructed 
to walk as fast as possible; in the Netherlands the instruction was to walk at their 
usual pace.
Time needed to complete the Timed Up and Go test (TUG) was measured. 
Participants were instructed to rise from a chair without use of arms, walk around 
a cone placed three meters from the chair and return to the original sitting position. 
Further instructions were to complete the test as quickly as possible, while taking 
care not to run and to remain safe. Participants were allowed three trials; the fastest 
attempt was used for analyses.
In the Netherlands, additional measurements included a physical fitness test, by 
estimating maximal oxygen uptake (VO2 max) according to the Astrand fitness test 
(15). This method has been shown to be a valid test in elderly participants (aged 60 to 
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Young (n=180) Old (n=281)
Age (years) 23.4 (2.9) 74.4 (3.3)
Females, n (%) 94 (52.2) 144 (48.8)
Living with partner 40 (22.2) 148 (52.7)
Highly educated, n (%)a 132 (73.3) 96 (34.2)
Anthropometry
Height (m) 1.73 (0.09) 1.67 (0.09)
Body mass (kg) 68.8 (12.3) 71.5 (12.8)
Body mass index (kg/m2) 22.8 (3.0) 25.5 (3.4)
Lifestyle
Excessive alcohol use, n (%)b 44 (24.4) 36 (12.8)
Current smoking, n (%) 23 (12.8) 13 (4.6)
Comorbidities
Number of diseases, median (IQR) 0 (0-0) 1 (0-1)
Number of medications, median (IQR) 0 (0-1) 1 (0-3)
Mental state
MMSE score (points), median (IQR) 30 (29-30) 29 (28-30)
GDS score (points), median (IQR) 0 (0-1) 1 (0-2)
Diagnostic criteria for sarcopenia
Lean mass percentage (%)c 72.9 (9.1) 67.1 (8.3)
ALM percentage (%)d 33.1 (4.7) 28.7 (4.1)
ALM/height² (kg/m²) 7.5 (1.3) 7.2 (1.1)
Total lean mass (kg) 50.2 (11.3) 47.7 (9.9)
Knee extension torque (Nm) 197.5 (69.5) 124.3 (44.1)
Handgrip strength (kg) 42.4 (12.2) 32.9 (9.4)
Physical performance
TUG (s)e 4.86 (0.91) 6.37 (1.16)
Walking speed (m/s)f 1.85 (0.30) 1.46 (0.22)
Physical fitness (ml/kg/min)g 37.9 (9.0) 25.7 (6.4)
Table 1: Participant characteristics, stratified by age (n=461).
Variables are presented as mean and standard deviation, unless indicated otherwise. aData available in 
n=344. bExcessive alcohol used defined as for males > 21 units/week and females > 14 units/week. cTotal 
lean mass as percentage of total body mass. dALM as percentage of total body mass. eData available in 
n= 457. fData available in n=450. gExpressed as the estimate of maximal oxygen uptake as derived from 
the Astrand fitness test, data available in a subgroup of n=108. MMSE: mini mental state examination. 
GDS: geriatric depression scale. TUG: Timed Up and Go test. ALM: appendicular lean mass. 
Diagnostic criteria for sarcopenia and physical performance
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70 years) (16). Participants pedalled at a cadence of 60 cycles per minutes (rpm) on a 
cycle ergometer at a selected workload (50, 75, 100 or 150 Watt) during six minutes. 
The workload was selected by asking subjects about their daily activity level and 
training status, and by taking age and gender into account. The workload was aimed 
to be at the highest tolerated intensity to ensure a heart rate of 110 beats per minute 
(bpm) after six minutes. Heart rate was measured continuously during the test using 
a polar heart rate monitor (Polar RS800CX, polar pro trainer 5). After a four minute 
warming up at a lower workload, the six minute Astrand fitness test was performed 
at the selected workload. If mean steady state heart rate (submaximal heart rate) at 
the end of the test was over 110 bpm, the test was ended. If the submaximal heart rate 
was below 110 bpm, the workload was increased and the test continued for another 
six minutes, if tolerated by the participant (17). The Astrand nomogram was used to 
calculate physical fitness (ml/kg/min) from submaximal heart rate, workload, body 
mass and gender (15).
Participant characteristics and health status
Standing height was measured to the nearest millimeter. Information about lifestyle 
factors such as smoking, alcohol use, living status, and education were self-reported 
using a questionnaire. Excessive alcohol use was defined as more than 21 units per 
week for men, or more than 14 units per week for women. Diseases were registered 
and categorized into cardiovascular disease (including cardiovascular events, arterial 
surgery, and hypertension), non insulin dependent diabetes mellitus, mild COPD, 
thyroid disease, and osteoarthritis. The sum score of diseases was calculated. The 
use of medication was registered and a sum score of all oral and inhaled medication 
was calculated as measure of disease severity. Cognitive function was measured by 
use of the Mini Mental State Examination (MMSE) and depressive symptoms were 
measured by using the Geriatric Depression Scale (GDS). 
Statistical analysis
Continuous variables with Gaussian distribution are presented as mean (standard 
deviation) and those with non-Gaussian distribution as median (interquartile range 
(IQR)).
Results from the different countries were first analyzed separately, and subsequently 
pooled if the effect sizes were comparable. In pooled analyses, all described diagnostic 
criteria for sarcopenia and physical performance parameters were standardized into 
country specific z-scores, to minimize possible effects due to differences in equipment 
and to allow comparison of effect sizes of diagnostic criteria for sarcopenia in their 
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association with physical performance. 
Linear regression analyses were used to identify associations between diagnostic 
criteria for sarcopenia and physical performance, and to calculate adjusted means 
and standard errors of the means. Adjusted means, and standard errors of the means 
were calculated for sex and country specific tertiles of the muscle characteristics. 
Three different adjustment models were used, stratified by age category. In model 1 
analyses were adjusted for age (for residual confounding for age), sex, and country. In 
model 2 further adjustments were made for body mass or body fat, and additionally 
for height in model 3. Lean mass percentage and ALM percentage were adjusted for 
body mass since higher body mass is associated with physical performance and with 
lower relative muscle mass. As relative muscle mass is not associated with height, 
height was not included in the adjustment model. Lean mass and ALM/height2 were 
adjusted for fat mass, since these measures do not take fat mass into account. These 
measures were not adjusted for height as ALM/height2 already includes height. Knee 
extension torque and handgrip strength were adjusted for body mass and height. 
Adjustment models for the association between diagnostic criteria for sarcopenia 
and physical fitness did not include body mass or fat mass, as the estimation of 
physical fitness is already adjusted for body mass.
Results of the regression analyses with standardized variables can be interpreted as 
follows: 1 standard deviation (SD) increase of diagnostic criteria for sarcopenia is 
related to the effect size (β)*SD change in physical performance. 
SPSS 20 for Windows was used for all analyses. P-values < 0.05 were considered 
statistically significant. 
Results
Participant characteristics and health status
Baseline characteristics of the study participants are shown in Table 1, stratified for 
age category. Overall, values for diagnostic criteria for sarcopenia and for physical 
performance were lower in old participants as compared to young participants. 
Diagnostic criteria for sarcopenia and physical performance
Muscle mass
Table 2 shows the association between relative and absolute muscle mass and walking 
speed and duration of TUG. Old participants with a higher relative muscle mass 
(lean mass percentage and ALM percentage) had a faster walking speed and shorter 
duration of TUG. Additional adjustments for body mass affected the results only 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Young (n=34) Old (n=74) 
 β SE p β SE p
Relative muscle 
mass
Lean mass (% in SD)b
Model 1: age, sex 0.91 0.19 <0.001 0.59 0.11 <0.001
ALM (% in SD)c
Model 1: age, sex 1.00 0.25 <0.001 0.57 0.11 <0.001
Absolute muscle 
mass
ALM/height² (kg/m² in SD)
Model 1: age, sex -0.10 0.21 0.64 -0.05 0.11 0.65
Total lean mass (kg in SD)
Model 1: age, sex -0.10 0.29 0.74 -0.25 0.14 0.09
Muscle strength Knee extension torque (Nm in SD)
Model 1: age, sex -0.10 0.32 0.76 0.07 0.16 0.65
Model 2: as 1 and height -0.09 0.34 0.80 0.07 0.16 0.65
Handgrip strength (kg in SD)
Model 1: age, sex 0.03 0.24 0.90 -0.09 0.13 0.48
Model 2: as 1 and height 0.04 0.25 0.88 -0.07 0.13 0.57
Table 3: Association between diagnostic criteria for sarcopenia and physical 
performance (physical fitness) expressed as the estimate of maximal oxygen uptake 
as derived from the Astrand fitness test.
All diagnostic criteria for sarcopenia and physical fitness were standardized into z-scores. aExpressed as 
the estimate of maximal oxygen uptake as derived from the Astrand fitness test; bLean mass as percentage 
of total body mass; cALM as percentage of total body mass. ALM: appendicular lean mass. All p-values are 
assessed with linear regression and adjustments in separate models. Bold indicates significance (p<0.05).
slightly. There were no associations between absolute muscle mass (ALM/height2 
and total lean mass) and walking speed or TUG. Only when additional adjustment 
for fat mass was applied, ALM/height2 and lean mass were associated with faster 
walking speed, but not with TUG. There were no associations between relative or 
absolute muscle mass and walking speed or TUG in young participants. Results did 
not change after excluding participants from the Netherlands who were instructed 
to walk at their usual pace during the 6 minute walking test.
Table 3 shows the association between relative and absolute muscle mass and 
physical fitness. Relative muscle mass was positively associated with physical 
fitness in young and old participants. Absolute muscle mass was not associated with 
physical fitness. 
Muscle strength
Table 2 shows the association of muscle strength with walking speed and TUG. 
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Figure: Representation of the association between sex and country specific tertiles of different 
diagnostic criteria for sarcopenia and physical performance in old participants. Physical 
performance in A: Timed Up and Go test (TUG) and walking speed derived from 6 minutes 
walking test; in B: Physical fitness expressed as the estimate of maximal oxygen uptake as 
derived from Astrand fitness test. Muscle characteristics are ALM as percentage of body 
mass, ALM divided by height squared (ALM/height2) and knee extension torque. Bars 
indicate adjusted means and standard errors. All p-values are assessed with linear regression 
analyses including adjustments for gender and age (and country in A). ALM: appendicular 
lean mass.
Old participants with higher knee extension torque had a faster walking speed and 
shorter duration of TUG. After additional adjustments for body mass and height, the 
associations remained significant. Old participants with higher handgrip strength 
had a faster walking speed in all adjusted models. Higher handgrip strength was 
only associated with TUG after adjustment for body mass. There were no associations 
between knee extension torque or handgrip strength and walking speed or TUG in 
young participants. 
As shown in Table 3, no associations between knee extension torque or handgrip 
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strength and physical fitness in young and old participants were found.
Comparison of diagnostic criteria for sarcopenia
To determine the strongest association of different diagnostic criteria for sarcopenia 
with physical performance, effect sizes (β) for these associations given in Table 2 
and Table 3 were compared. In Table 2 including all participants, effect sizes (β) 
were strongest for relative muscle mass and muscle strength in the association with 
walking speed and TUG in old participants. In Table 3 including a subgroup of 
participants, effect sizes (β) were strongest for relative muscle mass in the association 
with physical fitness in young and old participants .
Figure 1 visualizes the association between tertiles of diagnostic criteria for sarcopenia 
and physical performance in old participants. Relative muscle mass is represented 
by ALM percentage, absolute muscle mass by ALM/height2 and muscle strength by 
knee extension torque. Relative muscle mass was the only diagnostic criterion for 
sarcopenia associated with all tested parameters of physical performance: walking 
speed, TUG, and physical fitness.
Discussion 
In this cross-sectional study, relative muscle mass expressed as lean mass 
percentage or ALM percentage was most associated with physical performance 
in old participants. Absolute muscle mass, expressed as ALM/height2 and total 
lean mass, was only associated with TUG after adjustment for fat mass, and not 
associated with walking speed and physical fitness. This indicates that diagnostic 
criteria for sarcopenia based on unadjusted ALM/height2 are not useful to predict 
physical performance. Greater muscle strength was associated with faster TUG and 
faster walking speed, but not with physical fitness. In young participants, diagnostic 
criteria for sarcopenia were not associated with TUG or walking speed, but there 
was a positive association between relative muscle mass and physical fitness.
Relative muscle mass expressed as ALM percentage or lean mass percentage was 
also a predictor for physical performance in other studies (8-10;12). Although the 
formula ALM/height2 proposed by Baumgartner et al. (1) is the most commonly 
used diagnostic criterion for sarcopenia, we found no association between ALM/
height2 and physical performance without adjusting for fat mass. Studies reporting 
significant associations between ALM/height2 and physical performance included 
adjustment models for fat percentage (1) or fat mass (10), which is in line with the 
present study, although we assessed ALM/height2 on a continuous scale. Without 
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adjustments for fat mass, absence of an association between ALM/height2 and 
physical performance or self-reported physical limitation is confirmed by other 
studies (11-13;18-20). In addition, no association was observed between total lean 
mass in kilograms and self-reported mobility limitation (14).
Differences between relative and absolute muscle mass can be explained by the 
role of fat mass. Most obese people have an increased muscle mass in addition to 
high fat mass, but may still have a low muscle mass relative to their body mass. 
Underweight elderly participants may have a high proportion of muscle mass in 
relation to their total body mass (9;21). With increasing chronological age, significant 
changes in body composition occur, including a decrease in bone and muscle mass 
and an increase in the proportion of fat mass, even when the body mass remains 
the same (19;22). The formula ALM/height2 underestimates sarcopenia in obese 
elderly and overestimates sarcopenia in underweight elderly participants (19;21;23). 
Therefore, it is important to take muscle mass relative to body mass or fat mass into 
account when defining sarcopenia (18;21;24).
In this study, muscle strength, in particular knee extension torque, was associated 
with the TUG test and walking speed in old participants, but not with physical 
fitness. Muscle strength has been associated with self-reported mobility limitation 
or physical performance (9;12;14;25), but not in all studies (13). Recently it has been 
advocated to use an index of muscle strength relative to body mass, which appeared 
to be strongly related to physical performance (25). It has been suggested that 
muscle strength in the elderly is associated with physical performance rather than 
muscle mass (25-27). However, in these studies, muscle mass was not adjusted for 
fat mass or body mass, indicating possible misclassification of low muscle mass (23). 
The loss of muscle mass is closely related to the loss of muscle strength, although 
not at the same rate (26). Using muscle strength to define sarcopenia has several 
limitations. To generate strength, other factors such as cardiovascular function, joint 
function and neural control are involved (28-30). Furthermore, muscle strength can 
be underestimated due to pain (4;23). 
In young participants, no association was found for diagnostic criteria for saropenia 
with TUG and walking speed. However, relative muscle mass was associated with 
physical fitness. This may be explained by the degree of challenge of these tests. For 
young participants, the TUG and the six minute walking tests were submaximal and 
did not require the full recruitment of muscle mass and strength. The differences 
between young participants in these tests may arise from differences in motivation, 
stride length and cardiorespiratory fitness. The Astrand fitness test is an individual 
challenging test. Under these circumstances even in young participants there are 
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differences in physical fitness which may be explained by their relative muscle mass. 
It should be noted that the Astrand nomogram already takes body mass into account 
to estimate oxygen uptake per kg body mass (but not muscle mass). 
The strength of this study was the comparison of the associations of relative muscle 
mass, absolute muscle mass, and muscle strength with physical performance, both 
in young and old participants. The inclusion of a large group of cognitively active 
and healthy participants across Europe minimizes the influence of diseases and 
cognitive impairment, although results cannot be generalized for the entire elderly 
population. Even though old participants were healthy and not likely to suffer 
from sarcopenia, age differences between young and old participants on diagnostic 
criteria for sarcopenia were clearly present. Results were analyzed using continuous 
data rather than dichotomizing on cut-off values. Therefore we cannot conclude on 
the use of cut-off values in sarcopenia. A weakness of this study is the cross-sectional 
design, which makes causal inference impossible .
In conclusion, when comparing different diagnostic criteria for sarcopenia, relative 
muscle mass was associated most consistently with physical performance, while 
ALM/height2 was only associated with physical performance after adjustments for 
fat mass were applied. This understanding is essential for the medical and scientific 
community to develop clinically applicable diagnostic criteria for sarcopenia. 
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Diagnostic criteria for sarcopenia relate differently to 
insulin resistance
AY Bijlsma, CGM Meskers, D van Heemst, RGJ Westendorp, AJM de Craen, AB 
Maier




Skeletal muscle is important in insulin-stimulated glucose uptake. Sarcopenia is 
therefore a possible risk factor for insulin resistance. Currently, different diagnostic 
criteria for sarcopenia include low muscle mass, muscle strength, and walking 
speed. We assessed these muscle characteristics in relation to insulin resistance in 
non-diabetics. This cross-sectional study included 301 non-diabetics, mean age 65.9 
years. Area under curve (AUC) calculations of insulin and glucose from a 2-hours 
oral glucose tolerance test and homeostasis model assessment of insulin resistance 
(HOMA-IR) were used as measures of insulin resistance. Muscle characteristics were 
relative muscle mass (total or appendicular lean mass (ALM) as percentage of body 
mass), absolute muscle mass (ALM/height2 and total lean mass), handgrip strength, 
and walking speed. All muscle characteristics were standardized and analyzed in 
linear regression models, stratified by gender. For both males and females, relative 
muscle mass was inversely associated with AUC insulin, AUC glucose, and HOMA-IR 
(ALM percentage all p≤0.004). Absolute muscle mass was positively associated with 
AUC insulin and HOMA-IR (ALM/height2 all p<0.001), but not with AUC glucose. 
Adjustments for fat mass attenuated aforementioned associations. There were no 
associations between handgrip strength and insulin resistance. Walking speed was 
inversely associated with AUC insulin in males (p=0.032). The association between 
muscle characteristics and insulin resistance was strongest for relative muscle mass. 
Diagnostic criteria for sarcopenia relate differently to insulin resistance. The role of 
muscle tissue as an internal glucose regulating organ is better reflected by relative 
muscle mass than by absolute muscle mass, muscle strength or walking speed. 




The term sarcopenia was introduced as a term to describe low muscle mass at older 
age (1;2), but has also been used to describe low muscle strength (3) or a low walking 
speed or muscle strength combined with low muscle mass (4;5). Although the clinical 
importance of low muscle mass is underscored by its associated increased risk of 
mortality (6), physical disability (2;7), and cognitive decline (8), no consensus on the 
definition of sarcopenia has been reached yet (4;5). Various quantification methods 
of muscle characteristics and correction factors have been proposed (2;3;7;9;10), 
which are mainly based on associations with disability in elders.   
Little attention has been paid so far to the role of various diagnostic criteria for 
sarcopenia in the association with insulin resistance. Insulin resistance has mainly 
been associated with higher body mass index (BMI)(11;12) and higher (visceral) fat 
percentage (13). Since skeletal muscle is accounting for approximately 75% of whole-
body insulin-stimulated glucose uptake (14), it is important to understand which 
diagnostic criteria for sarcopenia relate to glucose handling expressed as insulin 
resistance. Only few studies have investigated this association, with conflicting 
results. It was shown that a lower lean mass as percentage of body mass associated 
with insulin resistance (15). Other cross-sectional studies showed an association 
between a higher total lean mass (16) or quadriceps mass with insulin resistance, not 
taking possible confounders into account (17). After adjustment for weight or BMI, 
higher quadriceps mass and higher muscle strength were associated with a lower 
level of insulin resistance (17-19). These results indicate that important differences 
exist depending on which diagnostic criteria for sarcopenia are used, which is further 
complicated by the use of different adjustment models.
We hypothesized that a higher amount of muscle mass will generate a higher 
capacity for insulin-stimulated glucose uptake and will therefore be associated with 
a lower level of insulin resistance. We expect that this association is influenced by fat 
mass, which is positively associated with insulin resistance (20). Since there is little 
overlap in the prevalence of sarcopenia when different definitions are applied in the 
same study population (21), we expect that not all diagnostic criteria for sarcopenia 
are suitable to reflect muscle tissue as an internal glucose regulating organ. We 
expect that muscle mass will show a stronger association with insulin resistance 
than muscle strength and walking speed. To test these hypotheses, we examined the 
association between different diagnostic criteria for sarcopenia and valid measures 
of insulin resistance derived from an oral glucose tolerance test (OGTT) (22) in non-





Analyses were performed on a total of 301 middle aged and older adults including 
participants of the MYOAGE study and the Leiden Longevity Study (LLS).
The MYOAGE study comprises 35 young (aged 18 to 30 years) and 75 relatively 
healthy and cognitively active older participants (aged 69 to 81 years), recruited 
in 2010 and 2011 in Leiden, the Netherlands, as part of a European cohort study. 
The group of elderly participants was recruited based on their activity levels (high 
or relatively low). Application of exclusion criteria was aimed to select healthy 
participants, minimizing the confounding effect of disease on muscle mass, 
i.e. dependent living situation, unable to walk a distance of 250 m, presence of 
comorbidity (neurologic disorders; metabolic diseases; rheumatic diseases; recent 
malignancy; heart failure; severe chronic obstructive pulmonary disease (COPD); 
haemocoagulative syndromes), use of specified medication (immunosuppressive 
drugs, insulin, anticoagulation), immobilization for one week during the last three 
months, and orthopedic surgery during the last two years or still causing pain or 
functional limitation. For the present analyses, only the subgroup of older adults 
was selected; four participants were excluded due to previous history of diabetes 
mellitus, and one participant due to missing data on body composition, and the 
remaining 70 participants were included for analyses. 
The LLS consists of long-living Caucasian siblings of 420 families together with their 
middle aged offspring, and the partners of the offspring as controls (23). The study 
included 674 participants of the middle aged to older offspring and their partners, 
who were assessed in the period from 2006 to 2008 (23). There were no selection 
criteria on health or demographic characteristics (24). A subgroup of 380 middle-aged 
participants living in close proximity to the research center were invited to come to 
the research center in a fasting state; 274 of these participants agreed to participate. 
For the present analysis, 24 participants were excluded because of previous history 
of diabetes mellitus, 15 because of unreliable OGTT, one because of nonadherence to 
the fasting state, and three were excluded due to missing data on body composition 
(25), and the remaining 231 were included for analyses.
The Medical Ethics Committee of the Leiden University Medical Centre approved 
both studies, and written informed consent was obtained from all participants.
Oral glucose tolerance test
After 12 hours of fasting, glucose tolerance as a measure of insulin resistance was 
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assessed according to 2-hours OGTT, conducted with a standard loading dose of 
75 g of glucose in 0.3 L of water. Venous blood samples were drawn at time points 
0, 30, 60 and 120 minutes in both studies, and additionally at 15 and 90 minutes 
in the MYOAGE study cohort. All serum measurements were performed using 
fully automated equipment. For insulin levels, the Immulite 2,500 from DPC (Los 
Angeles, CA) and for glucose, the Hitachi Modular P800 from Roche (Almere, The 
Netherlands) was used. 
Assessment of body composition  
In the MYOAGE study, body composition was measured by Dual-energy X-
ray absorptiometry (DXA) (Hologic QDR 4500, Hologic Inc., Bedford, USA). 
Measurements were performed with dual-energy X-ray beams at 60 and 140 KeV, 
operated by a trained technologist. Single rectilinear scanning mode was used on 
a 148 x 330 pixel matrix in a 196 x 80 cm window. Standard regions were drawn 
and adapted manually when necessary.
In the LLS, body composition was measured using Direct Segmental Multi-frequency 
Bioelectrical Impedance Analysis (BIA) (In-Body (720) body composition analyzer, 
Biospace Co., Ltd, Seoul, Korea). We have previously shown this technique to be a 
valid tool for the assessment of whole body composition and segmental lean mass 
measurements in our sample of middle aged people (26). Excellent agreements were 
observed between BIA and DXA in total lean mass (intraclass correlation coefficient 
(ICC) female=0.95, p<0.001, ICC male=0.96, p<0.001) and fat mass (ICC female 0.97 
p<0.001, ICC male 0.93 p<0.001) (26).
Diagnostic criteria for sarcopenia
As described previously, muscle mass was grouped into relative and absolute 
measures (27). Relative muscle mass corrects muscle mass for body mass and was 
defined as lean mass divided by body mass in percentage,(7) or appendicular lean 
mass (ALM, the sum of lean mass of both arms and legs) divided by body mass 
in percentage (27). Absolute muscle mass was defined as ALM divided by height 
squared (ALM/height2) (2), or total lean mass in kilograms (28). 
Handgrip strength was measured with a Jamar dynamometer (Sammons Preston 
Inc, Bolingbrook, IL). All participants were asked to stand upright and hold the 
dynamometer in the hand with the arm parallel to the body without squeezing the 
arm against the body. The width of the handle was adjusted to the size of the hand. 
The participant was allowed to perform three trials with both the right and the left 
hand and the best score was used for analyses.
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Walking speed was measured during a 4 meter walking test from a standing start. 
Participants were instructed to walk at normal pace to the end of the corridor to 
prevent slowing down before the 4 meter line (29). Duration of the 4 meter walking 
test was recorded using a sensor unit containing accelerometers and gyroscopes 
(DynaPort Hybrid, McRoberts, The Netherlands), attached with a waist strap. 
Participant characteristics
Height and body mass were collected for all participants. Comorbidity was defined 
as a sum score of diseases including myocardial infarction, stroke, hypertension, 
arthritis, chronic obstructive pulmonary disease, and malignancy. Smoking was 
defined as current smoking or past smoking with more than ten pack years. The 
presence of sarcopenia was assessed according to cut-off values for ALM/height2 
(for males below 7.26 kg/m2 and for females below 5.5 kg/m2 (2)), and with a walking 
speed below 0.8 m/sec, or grip strength below cut-off (30 kg for males and 20 kg for 
females) (4).
Statistical analyses
Continuous variables with Gaussian distribution are presented as mean (standard 
deviation) and those with non-Gaussian distribution as median (interquartile range 
(IQR)). Variables with non-Gaussian distribution were logarithmically transformed 
and used in all calculations. OGTT derived area under the curves (AUCs) were 
calculated using the trapezoid rule (22); the homeostasis model assessment for 
insulin resistance (HOMA-IR) was calculated by dividing the product of fasting 
glucose level (in millimol per L) and fasting insulin level (in milliunit per liter) by 
22.5 (30).
All muscle characteristics were standardized in Z scores in order to compare effect 
estimates. The associations between muscle characteristics and insulin resistance 
were assessed using linear regression models, stratified by sex. In the first model, 
analysis was adjusted for age, gender and cohort. In the second model, further 
adjustments for fat mass were applied. For combined analyses of males and females, 
sex-specific tertiles of ALM percentage and ALM/height2 were calculated. In this 
combined analyses, regression analyses were adjusted for age, cohort, and sex. 
Differences between muscle characteristics for the association with OGTT derived 
measures of insulin resistance were tested for significance, without taking covariance 
into account, using Z values calculated with the formula ((b1 – b2)/ √(se2 +se2)) and p 
values derived from the standard normal distribution table. SPSS 17.0 for Windows 
was used for all analyses. P-values <0.05 were considered statistically significant. 
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Male (N=146) Female (N=155)
Age (y) 67.4 (7.1) 64.4 (7.7)
Females, n (%)
Height (m) 1.78 (0.06) 1.66 (0.06)
Total body mass (kg) 83.9 (11.2) 71.9 (11.2)
BMI (kg/m2) 26.4 (3.3) 26.0 (4.1)
Total number of diseases, median, (IQR)a 0 (0-1) 0 (0-1)
Smoking, n (%)b 95 (66.0) 67 (43.2)
Diagnostic criteria for sarcopenia
Lean mass percentage (%)c 71.5 (6.6) 62.0 (7.2)
ALM percentage (%)d 31.8 (3.1) 26.9 (3.0)
ALM/height2 (kg/m2)e 8.3 (0.7) 6.9 (0.7)
Total lean mass (kg) 59.6 (6.7) 44.1 (4.9)
Handgrip strength (kg) 43.8 (7.9) 28.8 (5.0)
Walking speed (m/s)f 1.1 (0.2) 1.2 (0.2)
OGTT derived measures of insulin resistance
Fasting glucose (mmol/L) 5.2 (0.6) 5.1 (0.5)
Fasting insulin, median, (IQR) (mU/L) 6.0 (4-10) 6.0 (3-9)
AUC insulin (median, IQR) 93.7 (62.2-139.0) 89.1 (65.8-139.3)
AUC glucose 14.6 (3.6) 14.3 (3.7)
HOMA-IR, median (IQR) 1.48 (0.81-2.22) 1.20 (0.65-2.10)
Table 1: Characteristics of study participants. 
All values are expressed as mean (standard deviation), unless indicated otherwise. aSum score of to-
tal number of diseases (myocardial infarction, stroke, hypertension, arthritis, chronic obstructive pul-
monary disease, malignancy). bSmoking was defined as current smoking or more than 10 pack years. 
cLean mass as percentage of total body mass. dALM as percentage of total body mass. eALM divided by 
squared height. fData available in a subgroup of N=159. BMI=body mass index; IQR=interquartile range; 
ALM=appendicular lean mass; OGTT=oral glucose tolerance test; AUC= area under curve measured dur-
ing 120 minutes oral glucose tolerance test.
Results 
Characteristics of the study participants are shown in table 1. The mean age of 
participants of the MYOAGE study was 74.1 years and 63.3 years of the LLS. Equal 
numbers of males and females were included in both cohorts. According to cut-off 
values for sarcopenia, 16 (5.3%) participants had low ALM/height2, of which 4 (1.7%) 
participants simultaneously had a low walking speed or grip strength.
Table 2 shows the results of the association between different standardized diagnostic 
criteria for sarcopenia and OGTT derived measures of insulin resistance. Overall, 
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associations were comparable in males and in females. Relative muscle mass, 
expressed as lean mass percentage and ALM percentage, was inversely associated 
with ln AUC insulin, AUC glucose, and ln HOMA-IR when adjusting for age and 
cohort (table 2). When adjusting for fat mass, the statistically significant inverse 
associations attenuated. Absolute muscle mass, expressed as ALM/height2 and total 
lean mass, was positively associated with AUC insulin and HOMA-IR, but not with 
AUC for glucose (table 2). When adjusting for fat mass, the positive associations 
with ln AUC insulin disappeared. The positive association between absolute muscle 
mass and ln HOMA-IR also disappeared in females after adjustments for fat mass, 
but remained statistically significant in males. There was no association between 
handgrip strength and the AUC for insulin, glucose and HOMA-IR in both models. 
In females, walking speed was not associated with the AUC for insulin, glucose and 
HOMA-IR. In males, walking speed was inversely associated with ln AUC insulin, 
but not with AUC glucose or ln HOMA-IR.
Relative muscle mass expressed as lean mass percentage and ALM percentage was 
most strongly inversely associated with AUC insulin, AUC glucose, and HOMA-IR. 
When comparing the effect estimates of lean mass percentage and ALM percentage 
given in table 2 (model 1), these were not statistically significantly different in 
their association with insulin resistance. In contrast, the effect estimates of lean 
mass percentage and ALM percentage were significantly different from the effect 
estimates of absolute muscle mass (ALM/height2 and total lean mass)(all p<0.001). 
Walking speed was inversely associated with AUC insulin in males, but with a lower 
effect estimate as compared to relative muscle mass (p<0.001).
Combined analyses for males and females are presented in figure 1. This figure 
visualizes the inverse association for relative muscle mass, and the positive association 
for absolute muscle mass with OGTT derived measures for insulin resistance.
Discussion
In middle aged and older non-diabetic adults diagnostic criteria for sarcopenia 
relate differently to insulin resistance. Relative muscle mass, expressed as lean mass 
percentage and ALM percentage, was inversely associated with OGTT derived 
measures of insulin resistance. After adjustment for fat mass this association 
attenuated. Absolute muscle mass, expressed as ALM/height2 and total lean mass, 
was positively associated with AUC insulin and HOMA-IR, and not associated with 
AUC glucose. After adjustment for fat mass, the association attenuated but remained 
significant for HOMA-IR in males. Handgrip strength was not associated with 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Sex-specific tertiles of the relative muscle mass ALM percentage (A, C, E) and 
absolute muscle mass ALM/height2 (B, D, F) in relation to OGTT derived measures of insu-
lin resistance. OGTT derived measures of insulin resistance: ln AUC insulin (A, B), AUC 
glucose (C,D), and ln HOMA-IR (E,F). Appendicular lean mass (ALM) percentage=ALM 
as percentage of total body mass; ALM/height2=ALM divided by squared height; OGTT=oral 
glucose tolerance test; AUC=area under curve measured during 120 minutes oral glucose 
tolerance test; HOMA-IR=Homeostasis model assessment for insulin resistance calculated 
as dividing the product of fasting glucose and insulin by 22.5. P for trend from linear regres-
sion analysis adjusted for cohort, gender, age. Bars indicate adjusted means and standard 
error. NS=not significant; *= P<0.001.   
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OGTT derived measures of insulin resistance. Walking speed was only associated 
with AUC insulin in males, and with a lower effect estimate as compared to relative 
muscle mass. To the best of our knowledge, this is the first study comparing different 
muscle characteristics included in diagnostic criteria for sarcopenia in the context of 
insulin resistance. We conclude that diagnostic criteria for sarcopenia cannot be used 
interchangeably. Relative muscle mass is the best predictor of insulin resistance in 
middle aged to older non-diabetic participants, which strengthens the case to define 
sarcopenia using relative muscle mass.
This study clearly shows that relative muscle mass is strongly related to OGTT 
derived measures of insulin resistance. The results are in accordance with previous 
studies. An inverse association was observed between relative muscle mass and 
insulin resistance as measured with HOMA-IR (15). Midthigh cross-sectional 
area as measured with computed tomography (CT), standardized for body mass 
was inversely associated with insulin resistance in older non-diabetic adults (31). 
Contrarily, absolute muscle mass, unadjusted for body mass, has been found to be 
associated with higher insulin resistance in cross-sectional analyses (16;17;32). 
In recent years some researchers preferred to define sarcopenia based on low walking 
speed or low muscle strength combined with low muscle mass, instead of muscle 
mass only (4;5). In this study we show that the role of muscle tissue as an internal 
glucose regulating organ is better reflected by muscle mass than by muscle strength 
or walking speed. This can be explained by involvement of other systems besides 
muscle mass in the generation of strength, such as neural control and joint function. 
Previous studies in older non-diabetic adults reporting on the association between 
muscle strength or walking speed and insulin resistance show conflicting results 
(17-19;33). In older adults, weight or BMI adjusted handgrip strength was inversely 
associated with insulin resistance (18;19). Barzilay et al. showed a trend towards a 
positive association between unadjusted quadriceps strength and HOMA-IR, but an 
inverse association with quadriceps strength divided by quadriceps mass (17). In the 
NHANES study no association was found between peak leg strength and HOMA-IR 
in men and women aged over 50 years, but there was an inverse association between 
insulin resistance and walking speed in men only (33). Comparing these studies is 
difficult since a variety of adjustment models and statistical methods were used.
The positive association between absolute muscle mass with insulin resistance can be 
explained by the effect of fat mass, since this association attenuated after adjustment 
for fat mass in this study. Adjusting muscle mass for height only, as was first suggested 
by Baumgartner (2), seems to be insufficient to account for the influence of fat mass. 
A higher lean mass at older age is often accompanied by a higher fat mass (10;27). 
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Fat mass is an inducer of insulin resistance by secretion of adipokines, inflammatory 
mediators, and growth factors, although some adipokines are associated with lower 
insulin resistance such as adiponectin. Tumor necrosis factor-α (TNF-α), adiponectin, 
and leptin are the main adipokines that appear to be involved in the cross-talk between 
fat mass and skeletal muscle mass (20). The secretion of inflammatory cytokines 
could also lead to a reduction in muscle mass, as in longitudinal studies TNF- α, 
interleukin-6, and C-reactive protein have been associated with loss of muscle mass 
(34;35). Future research is needed to further explore causal mechanisms. Another 
example of the interaction between muscle and fat, is that increased deposition of 
lipids in the myotubes leads to muscle lipoprotein lipase overexpression, which in 
turn is associated with insulin resistance (14). Furthermore, reduced mitochondrial 
function in aged muscle is associated with insulin resistance which may impair 
the stimulating action of insulin on mitochondrial protein synthesis and function. 
Through these closed loops, insulin resistance can increase the rate of loss of skeletal 
muscle mass and vice versa (16;32;36).
The strength of this study was the ability to compare different measures of muscle 
mass or muscle function in the association with insulin resistance. Furthermore, 
the use of OGTT is a more sensitive test for skeletal muscle insulin resistance than 
fasting estimates of insulin resistance such as HOMA-IR as was reported in previous 
studies (37;38). Fasting indices for insulin resistance such as the HOMA-IR primarily 
reflect hepatic insulin resistance (37;38). A clamp study would be the gold standard 
to differentiate between muscle insulin resistance and hepatic insulin resistance. 
The limitation of this study was that only cross-sectional data were available, which 
makes causal inference difficult. Study sample size was relatively small although this 
did not prevent meaningful results. Furthermore, we cannot generalize the results 
to older frail participants, as the study population consisted of relatively healthy 
middle aged and older participants. 
In conclusion, diagnostic criteria for sarcopenia relate differently to insulin resistance. 
Lower relative muscle mass is most strongly associated with insulin resistance. 
ALM/height2, the parameter most often used in literature to define sarcopenia, does 
not correct for body fat and is therefore an inadequate reflection of the association 
between muscle mass and insulin resistance. Handgrip strength and walking speed 
are not reflecting the role of muscle tissue as an internal glucose regulating organ. 
The definition of sarcopenia should include relative muscle mass hereby intrinsically 
adjusting for fat mass, to reflect its function as an internal organ. In future studies, 
assessment of relative muscle mass in larger study cohorts including the general 
population, could be of additional value to decide on cut-off values for a low relative 
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muscle mass as predictor of insulin resistance.
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Purpose: Diagnostic measures for sarcopenia utilize different measures of muscle 
mass, muscle strength, and physical performance. To understand differences 
between these measures, we determined the association with respect to whole body 
bone mineral density (BMD), as an example of muscle related clinical outcome. 
Methods: In the European cross-sectional study MYOAGE, 178 young (18-30 years) 
and 274 healthy old participants (69-81 years) were recruited. Body composition 
and BMD were evaluated using dual-energy X-ray densitometry. Diagnostic 
measures for sarcopenia were composed of lean mass as percentage of body mass, 
appendicular lean mass (ALM) as percentage of body mass, ALM divided by height 
squared (ALM/height2), knee extension torque, grip strength, walking speed, and 
Timed Up and Go test (TUG). Linear regression models were stratified for sex and 
age and adjusted for age and country, and body composition in separate models.
Results: Lean mass and ALM/height2 were positively associated with BMD (P<0.001). 
Significance remained in all sex and age subgroups after further adjustment for 
fat mass except in old women. Lean mass percentage and ALM percentage were 
inversely associated with BMD in old women (P<0.001). These inverse associations 
disappeared after adjustment for body mass. Knee extension torque and handgrip 
strength were positively associated with BMD in all subgroups (P<0.01) except in old 
women. Walking speed and TUG were not related to BMD. 
Conclusions: The associations between diagnostic measures of sarcopenia and 
BMD as an example of muscle related outcome vary widely. Differences between 
diagnostic measures should be taken into account when studying sarcopenia.




Annual loss of muscle mass has been reported to be 1 to 2 percent per year after the 
age of 50 years (1). Sarcopenia was the term used to describe deficiency of muscle 
mass in old age. However, consensus on the definition of sarcopenia is lacking. Since 
the introduction of the term in 1988 (2), different diagnostic measures have been 
proposed to define sarcopenia, including muscle mass, muscle strength, and physical 
performance (i.e. walking speed) (3;4). Furthermore, it is unclear which correction 
factors for these measures should be used (5-7). Research on diagnostic measures for 
sarcopenia is of emerging importance, since the prevalence of sarcopenia is highly 
dependent on the applied diagnostic measures (8). 
Evidence-based consensus on the most clinically relevant diagnostic measures for 
sarcopenia, requires exploration of their association with muscle related clinical 
outcome. It is important to note that muscle tissue is not only a force generator but 
also important in glucose homeostasis (9;10), drug distribution (11), and as a reserve 
of body proteins that can be used in extreme conditions of stress or malnutrition 
(12;13). Another example of muscle related clinical outcome is bone mineral density 
(BMD) (14-16). The main explanation for an association between muscle and BMD 
is mechanical loading by gravitational forces that stimulates bone formation, as was 
first recognized for body mass (16;17). Several diagnostic measures for sarcopenia, 
i.e. muscle mass (14-16), muscle strength (18;19), and gait speed (20;21) have been 
associated with BMD with inconsistent results. Whether differences can be explained 
by study design, demographic characteristics (i.e. sex, age, ethnicity), and/or 
correction factors (such as body mass and fat mass) remains largely unknown. 
In the present study we compared the association of diagnostic criteria for sarcopenia 
with respect to BMD in healthy young and old men and women. 
Methods
Study design 
The MYOAGE study is a cross-sectional European multicenter study of young (aged 
18 to 30 years) and relatively healthy old participants (aged 69 to 81 years). The 
group of old participants was selected based on self-reported activity levels into 
a physically active group and a physically less-active group. Participants were 
recruited by focused advertisement in newspapers, the third generation university, 
association of emeriti and universities, thus selecting cognitively active individuals. 
Third generation university is a series of lectures, courses, seminars and trips 
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(cultural, educational or recreational) organized by the university for older people 
for their further learning and to increase social activities. In total, 461 participants 
were included consisting of 110 recruited in Leiden, the Netherlands, 105 in 
Jyvaskyla, Finland, 100 in Tartu, Estonia, 62 in Paris, France, and 84 in Manchester, 
United Kingdom. Nine participants were excluded because of missing results on 
body composition from the Dual-energy X-ray absorptiometry (DXA). Thus, the 
total number of participants in this analysis was 452.
Exclusion criteria were aimed to ensure selection of healthy participants and 
minimize the confounding effect of comorbidity on sarcopenia. In short, exclusion 
criteria were: dependent living situation, unable to walk a distance of 250 m, presence 
of morbidity (neurologic disorders, metabolic diseases, rheumatic diseases, recent 
malignancy, heart failure, severe chronic obstructive pulmonary disease (COPD), 
haemocoagulative syndromes), use of medication (immunosuppressive drugs, 
insulin), immobilization for 1 week during last 3 months, and orthopedic surgery 
during the last two years or still causing pain or functional limitation.
Measurements were performed according to unified standard operating procedures 
during visits to the local study centers. The local medical ethical committees of the 
respective institutions approved the study. Written informed consent was obtained 
from all participants.
Dual-energy X-ray absorptiometry
A whole body scan was performed using Dual-energy X-ray absorptiometry (DXA) 
(Netherlands: Hologic QDR 4500, version 12.4, Hologic Inc., Bedford, USA; Finland: 
Lunar Prodigy, version EnCore 9.30; Estonia: Lunar Prodigy Advanced, version 
EnCore 10.51.006; France: Lunar Prodigy, version EnCore 12.30; United Kingdom: 
Lunar Prodigy Advance, version EnCore 10.50.086). Additionally bone mineral 
density at the hip region was scanned in 347 participants, and T scores were derived 
based on reference values (49). During the measurements a light cotton shirt was 
worn by the participants, reducing measurement errors due to clothing absorption. 
A trained technician performed the dual-energy X-ray absorptiometry. From the 
DXA, whole body BMD, and total and compartmental lean mass and fat mass were 
measured. Lean mass was used as an estimate of muscle mass.
Components of body mass
In this article, body mass, lean mass, and fat mass are summarized into the term 
‘components of body mass’.
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Diagnostic measures for sarcopenia
Diagnostic measures were divided into measures of muscle mass, muscle strength 
and physical performance. 
Muscle mass
Lean mass percentage was calculated as lean mass divided by body mass in percentage 
(22b). Appendicular lean mass (ALM) percentage was calculated as the sum of lean 
mass of arms and legs divided by body mass in percentage (7). ALM divided by 
height squared (ALM/height2) was calculated as proposed by Baumgartner (5). 
Muscle strength
Isometric knee extension torque was measured with a knee extension dynamometer 
chair (Netherlands: Forcelink B.V., Culemborg, the Netherlands; Finland: custom 
made; Estonia: custom made; France: Biodex system 3 Pro isokinetic dynamometer, 
Biodex Medical Systems, Shirley, New York, USA; UK: custom made). The 
participants were positioned in an upright position, with straps to fix the hips to the 
chair and the ankle to a force or torque transducer at the knee angle of 90 degrees. 
Lever arm length was recorded as the distance between the knee axis of rotation and 
the middle of the pad. After three warm up trials at 50 % and 90 % of self-perceived 
maximal strength, three trials were conducted to measure maximal voluntary 
contraction (MVC) force of the knee extension muscle. For each attempt, maximal 
force or torque was recorded by the transducer and saved on the computer. Each 
trial was separated by one minute of rest. Knee extension torque was obtained either 
directly or by multiplying recorded peak force with the lever arm length. The trial 
with the highest torque output was taken for analyses.
Handgrip strength was measured using the Jamar dynamometer handle (Sammons 
Preston Inc, Bolingbrook, IL). The width of the dynamometer was adjusted for each 
participant separately for optimal fit. Participants were instructed to stand upright 
and with the dynamometer besides but not against their body. For both hands 
the strength was measured three times and recorded in kilograms. The best of all 
attempts was used for further analysis. 
Physical performance
Walking speed was measured as the average walking speed during a six-minute walk 
test. Participants were instructed to walk around cones placed 20 meters apart (or 25 
meters in France). In Finland, Estonia, France, and UK participants were instructed 




Young (n=85) Old (n=132) Young (n=93) Old (n=142)
Age (years) 23.6 (2.9) 74.9 (3.3) 23.2 (2.8) 74.2 (3.2)
Height (m) 1.80 (0.06) 1.74 (0.06) 1.67 (0.06) 1.61 (0.06)
BMI (kg/m2) 23.3 (3.1) 25.9 (3.1) 22.4 (3.0) 25.1 (3.6)
MMSE 30 (29-30) 29 (28-29) 30 (29-30) 29 (28-30)
GDS (median, IQR) 0 (0-1) 1 (0-2) 0 (0-1) 1 (0-2)
Number of comorbiditya (median, IQR) 0 (0-0) 1 (0-1) 0 (0-0) 1 (0-1)
Number of medicationb (median, IQR) 0 (0-0) 1 (0-3) 0 (0-1) 1 (0-3)
Osteoporosis medicationc (n,%) 4 (4.7) 14 (10.6) 1 (1.1) 42 (29.6)
Current smoking (n,%) 9 (10.6) 8 (6.1) 13 (14.0) 5 (3.5)
Excessive alcohol usedd (n,%) 25 (29.4) 23 (17.4) 19 (20.4) 13 (9.2)
Table 1: Participant characteristics stratified by sex and age (n=452).
Variables presented as mean and standard deviation, unless indicated otherwise. aTotal number of co-
morbidity includes cardiovascular disease, osteoarthritis, thyroid disease, diabetes mellitus and other 
diseases. bNumber of medication is the total number of inhaled and oral medication. cNumber of par-
ticipants using either bisphosphonates, calcium, or vitamin D. dExcessive alcohol use was determined 
as >210 g/week for men and >140 g/week for women. BMI: body mass index. GDS: Geriatric Depression 
Scale. MMSE: Mini Mental State Examination.
to walk at usual pace.
Time needed to complete the Timed Up and Go test (TUG) was measured. 
Participants were instructed to stand up from a chair without use of arms, walk 
around a cone placed three meters from the chair and return to the original sitting 
position. Further instructions were to complete the test as quickly as possible, while 
taking care not to run and to remain safe. Participants were allowed three trials, and 
the fastest attempt was used for analyses.
Participant characteristics and health status
Standing height was measured for each participant. Information about lifestyle 
factors such as smoking, alcohol use, living status, and education were self-reported 
using a questionnaire. Excessive alcohol use was defined as more than 21 units 
per week for men, or more than 14 units per week for women. Morbidities were 
registered and categorized into cardiovascular disease (including cardiovascular 
events, arterial surgery, and hypertension), non insulin dependent diabetes mellitus, 
mild COPD, thyroid disease, and osteoarthritis. Sum score of diseases including 
these diseases was calculated. The use of medication was registered and a sum score 
of all oral and inhaled medication was calculated as measure of disease severity. Use 
of bisphophonates, calcium and vitamin D (separately or combined) was grouped 
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under the term ‘osteoporosis medication’. Cognitive function was measured by 
use of the Mini Mental State Examination (MMSE) and depressive symptoms were 
measured by using the Geriatric Depression Scale (GDS). 
Statistics 
Continuous variables with Gaussian distribution are presented as mean (standard 
deviation) and those with non-Gaussian distribution as median (interquartile range 
(IQR)).
Results from the different countries were first analyzed separately, and were pooled 
if the effect sizes were comparable. In pooled analyses, all described diagnostic 
measures for sarcopenia, components of body mass and BMD were standardized 
into country specific Z-scores, to minimize possible effect due to differences in 
equipment. The standardization allowed for comparison between effect sizes of 
diagnostic measures for sarcopenia and components of body mass in their association 
with BMD.
Students T-test was used to calculate differences between young and old participants. 
Linear regression analyses were used to identify associations of components of 
body mass and diagnostic measures for sarcopenia with BMD. Two different 
adjustment models were used, stratified for sex and age group. In model 1 analyses 
were adjusted for age (for residual confounding for age) and country. In model 2 
further adjustments were made for appropriate measures of body composition. 
Lean mass and ALM/height2 were adjusted for fat mass, since these measures do 
not take fat mass into account. Lean mass percentage and ALM percentage were 
adjusted for body mass since higher body mass is associated with lower lean mass 
percentage and with higher BMD (34;50). Lean mass and fat mass were included in 
the same model to assess the independent contribution in the association with BMD. 
Results of the regression analyses with standardized variables can be interpreted as 
follows: 1 standard deviation (SD) increase of diagnostic measures for sarcopenia 
or components of body mass, is related to the effect size (β)*SD change in BMD. 




Participant characteristics stratified by sex and age group are presented in Table 1. 
All participants had a high MMSE score, low GDS score and a low number of co-
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morbidities and number of medication.
Age differences in BMD, components of body mass, and diagnostic  measures for 
sarcopenia
In Table 2, differences between young and old participants in measures of BMD, 
components of body mass and diagnostic measures for sarcopenia are presented for 
men and women separately. BMD was lower both in old men and in old women as 
compared to young men and women. Based on T score values below -2.5, 6 (5.6%) 
of old females were osteoporotic at the hip region. None of the young participants 
or old males were osteoporotic. Body mass did not differ between young and old 
participants. Compared to young participants, fat mass was higher both in old men 
and in old women. Old men had a lower muscle mass than young men (lean mass, 











Body BMD (g/cm2) 1.3 (0.01) 1.2 (0.01) <0.001 1.15 (0.01) 1.04 (0.01) <0.001
Components of body mass
Body mass (kg) 76.0 (1.3) 78.3 (1.0) 0.15 62.2 (1.0) 64.6 (0.9) 0.07
Fat mass (kg) 13.3 (0.7) 20.5 (0.7) <0.001 18.8 (0.7) 22.8 (0.6) <0.001
Lean mass (kg) 59.9 (0.8) 55.6 (0.6) <0.001 41.4 (0.6) 40.2 (0.5) 0.10
Diagnostic measures
Muscle mass
Lean mass (%)a 79.4 (0.7) 71.6 (0.6) <0.001 67.0 (0.7) 62.9 (0.6) <0.001
ALM (%)b 36.8 (0.3) 31.2 (0.3) <0.001 29.7 (0.3) 26.3 (0.3) <0.001
ALM/height2 (kg/m2) 8.6 (0.1) 8.0 (0.7) <0.001 6.6 (0.08) 6.5 (0.06) 0.33
Muscle strength
Knee extension torque (Nm) 249.0 (6.5) 152.2 (3.7) <0.001 150.3 (3.7) 97.5 (2.2) <0.001
Handgrip strength (Kg) 52.7 (1.0) 39.6 (0.7) <0.001 33.2 (0.5) 26.2 (0.4) <0.001
Physical performance
Walking speed (m/s) 1.94 (0.03) 1.48 (0.02) <0.001 1.76 (0.03) 1.44 (0.02) <0.001
TUG (s) 4.67 (0.10) 6.10 (0.10) <0.001 5.02 (0.09) 6.60 (0.09) <0.001
Table 2: Age differences in measures of bone mineral density, components of body 
mass and diagnostic measures for sarcopenia stratified by sex (n=452).
Variables presented as mean with s.e. of the mean. Students T-test was used to calculate the differences 
between young and old. aLean mass in percentage is the lean mass as percentage of body mass. bALM in 
percentage is the appendicular lean mass as percentage of body mass. BMD: whole body bone mineral 
density. TUG: Timed Up and Go test.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































young women for lean mass percentage, but not for lean mass in kilogram or ALM/
height2. Muscle strength (knee extension torque and handgrip strength), walking 
speed and performance on TUG were lower both in old men and in old women 
compared to young men and women. 
Components of body mass and BMD
Table 3 displays the results from linear regression analyses using standardized 
variables for the association of components of body mass with BMD, stratified by 
age and sex. In all groups, body mass was associated with BMD. Fat mass was 
associated with BMD in old men and old women, but not in young participants. 
Significance was lost in old men after adjustment for lean mass. In all groups 
there was a highly significant positive association between lean mass and BMD. 
Adjustment for fat mass affected these results only slightly, except in old women; in 
this group significance was lost. The association between components of body mass 
with BMD were visualized in Fig. 1.
Diagnostic measures for sarcopenia and BMD
Muscle mass
Table 3 shows the results from linear regression analyses using standardized variables, 
for the association of diagnostic measures for sarcopenia with BMD, stratified by 
age and sex. In young men, young women, and old men, lean mass percentage and 
ALM percentage were significantly associated with BMD after adjustments for body 
mass. In old women, lean mass percentage and ALM percentage were significantly 
inversely associated with BMD; after adjustment for body mass significance was lost. 
In all groups ALM/height2 was positively associated with BMD. After adjustment for 
fat mass, significance remained except in old women. The association between ALM 
percentage and ALM/height2  with BMD is visualized in Fig. 2.
 
Muscle strength 
The association of muscle strength and physical performance with BMD is shown 
in Table 4. Knee extension torque as well as handgrip strength were positively 
associated with BMD in young men, young women, and old men. This association 
remained significant in young men and young women with further adjustments for 
body mass. In old women, knee extension torque and handgrip strength were not 
associated with BMD. The association between knee extension torque and BMD is 
visualized in Fig. 2.




























































































































































































































































































































































































































































































































































































































































































































































Walking speed and TUG were not related to BMD. Discarding data from the 
Netherlands, where walking speed was measured at usual pace, did not change 
these results. The association for walking speed and BMD is visualized in Fig. 2.
Comparison of effect sizes
To determine the strongest association with BMD, effect sizes (β) for components 
of body mass (Table 3) and diagnostic measures for sarcopenia (Table 3 and 4) 
were compared in Tables 3 and 4. The effect size indicates the SD increase in BMD 
Figure 1: The association between components of body mass and whole body bone mineral 
density (BMD) in young men (a), old men (b), young women (c) and old women (d). Lean 
mass (kg), fat mass (kg), and body mass (kg) are presented in country, sex, and age specific 
tertiles. Bars represent the adjusted means and s.e. P values were calculated with linear 
regression models  for the association between components of body mass and BMD with 
adjustments for age and country. *=p<0.01. **=p<0.001. 
Diagnostic measures for sarcopenia and bone mineral density
115
7
with increase of 1 SD of the diagnostic measure. Lean mass showed the strongest 
association with BMD in all groups in the model adjusting for age and country. 
The association between tertiles of lean mass, fat mass, and body mass with BMD is 
displayed in Fig. 1, adjusted for age and country. Diagnostic criteria for sarcopenia 
are visualized in Fig. 2. Since effect sizes were similar in the association with BMD 
for ALM percentage and lean mass percentage only ALM percentage is depicted in 
Fig.2. Likewise, knee extension torque is representative of handgrip strength,  and 
walking speed is representative of TUG in Fig. 2. 
Discussion
In this cross-sectional European study of young and old participants, the main 
objective was to compare different diagnostic measures for sarcopenia and their 
association with BMD as a muscle related clinical outcome. We have shown that 
the associations of different diagnostic measures for sarcopenia with BMD varies 
substantially. Therefore, different diagnostic measures cannot be compared or 
interpreted interchangeably. Lean mass was most strongly related with BMD and 
positively associated with BMD when adjusted for age and country. ALM/height2 
was positively associated with BMD in all subgroups, although in old women this 
association was no longer present when further adjustments for fat mass were 
applied. Lean mass percentage and ALM percentage were inversely associated with 
BMD without adjustment for body mass in old women. Fat mass was associated 
with whole body BMD in older women, independent of lean mass. Muscle strength 
was associated with whole body BMD in young participants and older men, but not 
in women. Walking speed and TUG were not associated with BMD.
In the present study, lean mass was found to be most strongly associated with 
BMD. In a previous study comparing the association between different diagnostic 
measures for sarcopenia with glucose regulation, lean mass percentage was most 
associated with glucose tolerance (10). More research comparing diagnostic 
measures with relevant muscle related clinical outcome is needed before reaching a 
final consensus for the definition of sarcopenia. Muscle mass (5;22), muscle strength 
(23), and physical performance (3;4) have all been suggested to be included in the 
definition of sarcopenia with different correction factors, but evidence is lacking to 
decide on the most appropriate diagnostic measures. The use of muscle strength 
or walking speed for defining sarcopenia implies a constant ratio between these 
variables and muscle mass. This is not the case, as muscle strength declines much 
more with age than muscle mass, while muscle strength is positively but not linearly 
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associated with maximum walking speed (24;25). Therefore, it has been suggested to 
differentiate between the terms ‘sarcopenia’ and ‘dynapenia’ (26;27). Other factors 
in addition to muscle mass are important to generate muscle strength and physical 
performance such as neural control, cognition, cardiovascular and joint function (26). 
To keep terminology clear, we suggest to reserve the term sarcopenia for diagnostic 
measures based on muscle mass only, and not for muscle strength or walking speed. 
Diagnostic measures for sarcopenia based on muscle mass have been described 
previously in the association with BMD, although not all in a comparative way. In 
accordance with this study, lean mass in kilograms has been reported to have a 
positive association with BMD in several studies (14;15;28-31). ALM/height2 was 
positively associated with BMD in men without adjustment (16) and in another study 
after adjustments for age, fat mass, height, smoking, physical activity, and estradiol 
(32). In postmenopausal women with hip fracture, ALM/height2 was not associated 
with whole body BMD after adjustment for body fat (33). An inverse association 
between lean mass percentage and BMD has been described, whereas a positive 
association of lean mass in kilograms and BMD was found (34). These contradictory 
results for muscle mass measures may be explained by the inverse asscociation 
between lean mass percentage and total body mass, as with lower body mass there 
is less weight-bearing effect on bones. We have now confirmed that differences in 
results between studies, describing the association for a muscle mass measure with 
BMD,  may arise from different corrections for body composition (body mass or 
height), next to differences in characteristics of study populations.
In this study, muscle strength expressed as knee extension torque and handgrip 
strength was associated with BMD in all subgroups, except in old women. Previous 
studies have described an association between muscle strength and whole body 
BMD in postmenopausal women (18;19;35), but not all (36). This association 
generally disappeared after adjustment for body mass (18;35). It can be noted that 
these studies were of comparative size or smaller with respect to this study. In one 
study including 1380 women and 1265 men aged over 50 years (mean age 63.6 
years), low grip strength was associated with low BMD independent of body mass 
in women, but not in men (37).
The association between physical performance and BMD has been studied before 
(20;21;38). In line with this study, some groups reported no association between 
gait speed and BMD (20;38). However, other studies describe a positive association 
between gait speed and BMD (21;38). 
This study was aimed to investigate muscle ageing in healthy individuals in the 
absence of disease. Even though old participants were healthy, age differences 
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in muscle measures were clearly present. In particular old women were different 
from young women in the association between diagnostic measures for sarcopenia 
and BMD. These results may not be generalized to more frail populations who are 
more likely to suffer from multimorbidity and decreased physical activity including 
increased risk of falls and fractures in frail older women (46-48). Future studies
are needed to investigate the association between diagnostic measures for sarcopenia 
and BMD in frail populations.
Figure 2: The association between different diagnostic measures for sarcopenia and whole 
body bone mineral density (BMD) in young men (a), old men (b), young women (c) and 
old women (d). ALM in percentage is the appendicular lean mass as percentage of body 
mass. ALM percentage, ALM/height2 (kg/m2), knee extension torque (Nm) and walking 
speed (m/s) are presented in country, sex, and age group specific tertiles. Bars represent 
the adjusted means and s.e. P values for the association between diagnostic measures for 
sarcopenia and BMD were calculated with linear regression models with adjustments for age 
and country. *=p<0.01. **=p<0.001. 
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Loading of bones with a subsequent induction of bone formation by stimulation of the 
mechano-sensing osteocyte (17), is the most obvious pathophysiological link between 
BMD and measures of muscle mass, muscle strength, and physical performance. 
Mechanical stress exerted on bones is sensed by osteocytes which become activated 
and subsequently stimulate osteoblasts to increase BMD at site which is under most 
pressure (17). Both muscle and fat tissue contribute to this mechanism since body 
mass is predominantly composed out of these tissues. Muscles are connected to 
bones by tendons and are therefore in a position to apply stress directly onto the 
bones. This could explain the greater effect of muscle mass compared to fat mass 
on BMD. Since the absolute mass of both muscle and fat are beneficial for loading 
on bones, lean mass as a percentage of body mass does not reflect the direct effect 
of body mass on bones and is therefore less relevant with respect to mechanical 
loading of bones. Load exerted on bones by exercising has been shown to suppress 
BMD decline (39). In the present study, the association between muscle strength and 
BMD was strongest in the young participants and was independent of body mass. 
We hypothesize that in the young participants muscle strength might be a reflection 
of exercising which could stimulate of bone formation. Whereas at old age lifestyle 
becomes less active and the importance of the gravitational forces of body mass on 
bone maintenance would increase.
Hormonal and systemic factors should also be considered as explanation for the 
observed associations between lean mass, fat mass and BMD (40). This may be 
particularly relevant for women. The positive association between fat mass and BMD 
could be explained by adipokines secreted by fat tissue which might be beneficial for 
estrogen-deficient women after menopause. Adiponectin, insulin, amylin, preptin, 
leptin and adipocytic estrogens are all likely to contribute positively to BMD 
(34). For example leptin affects both bone formation and resorption by increasing 
proliferation and differentiation of osteoblasts, promoting bone nodule formation, 
increasing chondrocyte growth, and regulating osteoclast development (41). In 
postmenopausal women the role of the adipocyte as an estrogen-producing cell 
becomes more important, as estrogen influences bone density. Insulin increases free 
concentrations of both androgens and estrogens, which are positively associated 
with bone mass (34). Since muscle tissue is responsible for approximately 75 percent 
of insulin-mediated uptake of glucose, crosstalk between muscle and fat is of high 
importance (42). Furthermore, recent evidence suggests that a factor secreted by 
muscles, irisin, can decrease body mass in obesity and improve glucose homeostasis 
(43). It has become clear that osteocalcin, which is secreted by bone tissue, also affects 
energy metabolism (40). Studies on the contribution of fat mass on BMD have shown 
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inconsistent results, with an inverse (30;44), no (28;45), or a positive association 
(14;29;31). This study contributes to appreciate these inconsistencies, which arise 
(partially) from differences in sex and age. The important role of fat mass might 
explain why different results are observed in old women compared to old men.
The strength of this study was the ability to discriminate between the effects of 
both muscle mass and fat mass on BMD stratified for sex and age. The comparison 
of the associations of different diagnostic measures such as muscle strength and 
physical performance with BMD was performed. The inclusion of a large group of 
cognitively active and healthy participants across Europe minimizes the influence of 
diseases and cognitive impairment, although results cannot be generalized for the 
entire elderly population. Even though old participants were healthy and not likely 
to suffer from sarcopenia, age differences between young and old participants on 
diagnostic measures for sarcopenia were clearly present. A limitation of studying 
relatively healthy old participants is that we were not able to dichotomize into a 
sarcopenic and non-sarcopenic group based on currently available definitions 
for sarcopenia (3;4). Therefore we cannot conclude on the use of cut-off values in 
sarcopenia. A limitation of the adjustment models for body composition is the co-
linearity between fat and lean mass. As DXA measures areal rather than volumetric 
density, BMD is not completely corrected for skeletal size (34). Finally a limitation is 
the cross-sectional design of the study. 
In conclusion, the associations between several diagnostic measures for sarcopenia 
and BMD vary widely. Lean mass was most strongly associated with whole body 
BMD, and lean mass in percentage and ALM percentage are not appropriate to 
describe this association without further adjustment for body mass. Gait speed 
and TUG do not associate with BMD. This should be accounted for when defining 
sarcopenia. Future investigations should focus on the associations of diagnostic 
measures for sarcopenia with respect to other muscle related clinical outcome.
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Abstract 
Objectives: Assessment of the association of muscle characteristics with standing 
balance is of special interest as muscles are a target for potential intervention, i.e. by 
strength training. 
Design: Cross-sectional study
Setting: Geriatric outpatient clinic
Participants: The study included 197 community-dwelling elderly outpatients (78 
males, 119 females, mean age 82 years). 
Measurements: Muscle characteristics included handgrip and knee extension strength, 
appendicular lean mass divided by height squared (ALM/height2), and lean mass as 
percentage of body mass. Two aspects of standing balance were assessed: the ability 
to maintain balance, and the quality of balance measured by Center of Pressure 
(CoP) movement during ten seconds of side-by-side, semi-tandem and tandem 
stance, with both eyes open and eyes closed. Logistic and linear regression models 
were adjusted for age, and additionally for height, body mass, cognitive function 
and multimorbidity. 
Results: Handgrip and knee extension strength, adjusted for age, were positively 
related to the ability to maintain balance with eyes open in side-by-side (p=0.011; 
p=0.043), semi-tandem (p=0.005; p=0.021) and tandem stance (p=0.012; p=0.014), and 
with eyes closed in side-by-side (p=0.004; p=0.004) and semi-tandem stance (not 
significant; p=0.046). Additional adjustments affected the results only slightly. ALM/
height2 and lean mass percentage were not associated with the ability to maintain 
standing balance, except for an association between ALM/height2 and tandem stance 
with eyes open (p=0.033) that disappeared after additional adjustments. Muscle 
characteristics were not associated with CoP movement. 
Conclusion: Muscle strength rather than muscle mass was positively associated with 
the ability to maintain standing balance in elderly outpatients. Assessment of CoP 




Among 37 million elderly aged over 65 years, 7 million reported impaired standing 
balance in the past 12 months in the National Health Interview Survey in 2008 (1). 
Standing balance is dependent on integrated functioning of the sensory systems 
(vestibular, visual, and proprioceptive system), neural control, and muscle 
characteristics. These systems degenerate with increasing chronological age, by 
cumulative tissue damage, specific diseases and medication use (2-6). Muscle 
characteristics are of special interest, as recent evidence suggests that strength 
training can improve muscle strength and muscle mass, even in elderly (7-9). To 
develop targeted interventions for impaired standing balance in elderly outpatients, 
it is important to understand the contribution of muscle strength and muscle mass 
to standing balance. 
In healthy elderly it was shown that muscle strength is associated with the ability to 
maintain standing balance (10;11). Quadriceps muscle mass has also been associated 
with the ability to maintain standing balance in healthy elderly (12). Besides the ability 
to maintain standing balance, the quality of balance can be assessed additionally by 
measuring the Center of Pressure (CoP) movement. In healthy elderly, muscle mass 
(12;13) but not muscle strength has been associated with CoP movement (14-16). 
It remains unknown if associations between muscle characteristics and standing 
balance are present in elderly outpatients, while this group is obviously of clinical 
interest. These outpatients are more likely to suffer from multimorbidity and 
deterioration in more than one system involved in standing balance (11;17;18). Only 
few studies describe the association between muscle characteristics and standing 
balance in elderly with mobility difficulties, often applying exclusion criteria for co-
morbidity or severe mobility limitations (19;20). We assessed the association between 
muscle characteristics and two aspects of standing balance, the ability to maintain 
balance as well as the CoP movement, in community-dwelling elderly referred to a 
geriatric outpatient clinic. 
Methods
Setting
This cross-sectional study included 207 community-dwelling elderly who were 
referred to a geriatric outpatient clinic in a middle-sized teaching hospital (Bronovo 
Hospital, The Hague, Netherlands) for a comprehensive geriatric assessment (CGA) 
between March 2011 and January 2012. CGA was performed during a two hour visit 
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including questionnaires and physical and cognitive measurements. All tests were 
performed by trained nurses or medical staff. Medical charts were retrospectively 
evaluated. The study was reviewed and approved by the institutional review board of 
the Leiden University Medical Center (Leiden, the Netherlands). Because this research 
is based on regular patient care, the need for individual informed consent was waived. 
In the present analyses, 10 elderly outpatients (4.8%) were excluded due to missing 
data on standing balance, leaving 197 outpatients for analyses.
Elderly outpatient characteristics
Questionnaires included information on marital status, current smoking, alcohol use 
and living arrangements. Anthropometric data included assessment of body mass, 
height and body mass index. Information on diseases and use of medication was 
extracted from medical records. Multimorbidity was rated as the presence of two 
or more diseases, including chronic obstructive pulmonary disease, heart failure, 
diabetes mellitus, hypertension, malignancy, myocardial infarction, Parkinson’s 
disease, (osteo)arthritis, transient ischemic attack and stroke. The Hospital Anxiety 
and Depression scale (HADS) was used to detect depressive symptoms (21). A score 
higher than 8 out of 21 points indicated depressive symptoms. Global cognitive 
function was assessed using the Mini Mental State Examination (MMSE) (22). Physical 
functioning was self-reported in a questionnaire with questions on experienced falls 
during the last 12 months, walking difficulties, impaired standing balance and use 
of walking aids. Physical functioning was assessed with a 10 meter walking test at 
usual pace in steady state, and with the short physical performance battery (SPPB) 
(23). The SPPB comprises the ability to maintain balance in three different standing 
positions with eyes open, a timed four meter walk, and a timed sit-to-stand test. 
Standing balance 
The ability to maintain standing balance
The ability to maintain standing balance was tested in different standing conditions. 
Elderly outpatients, wearing non slip socks, were instructed to maintain balance 
for 10 seconds in each standing condition. Three different standing positions 
characterized by a progressive narrowing of the base of support were performed 
both with eyes open and eyes closed. During side-by-side stance, elderly outpatients 
were instructed to stand with the medial malleoli as close together as possible; 
during semi-tandem stance, elderly outpatients were standing with the medial side 
of the heel of one foot touching the big toe of the other foot; during tandem stance, 
elderly outpatients were standing with both feet in line while the heel of one foot 
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All (n=197) Male (n=78) Female (n=119)
Age, years 81.9 (7.1) 80.7 (6.8) 82.7 (7.2)
Widowed, n (%) a 80 (41.5) 17 (21.8) 63 (54.8)
Living arrangements, n (%) a 
Institutionalized 0 (0) 0 (0.0) 0 (0.0)
Sheltered 40 (20.6) 13 (16.9) 27 (23.1)
Independent 154 (79.4) 64 (83.1) 90 (76.9)
Current smoking, n (%) b 22 (16.2) 9 (16.1) 13 (16.3)
Excessive alcohol use, n (%) # 8 (4.1) 5 (6.4) 3 (2.5)
Body mass, kg 71.8 (15.5) 78.7 (12.1) 67.3 (15.8)
Height, cm 167 (10) 176 (7) 161 (6)
BMI, kg/m2 25.8 (4.5) 25.5 (3.6) 25.9 (5.0)
Multimorbidity, n (%) c, † 95 (50.3) 43 (55.1) 52 (46.8)
Number of medication, median (IQR) c 5 (3-7) 6 (3-7) 5 (2-7)
Depressive symptoms, n (%) d, ‡ 28 (23.1) 17 (30.9) 11 (16.7)
MMSE, points; median (IQR) 27 (24-29) 27 (25-29) 27 (24-29)
Gait speed, m/s 0.87 (0.29) 0.93 (0.31) 0.83 (0.27)
SPPB, points; median (IQR) 7 (5-10) 8 (6-10) 7 (5-9)
Self-reported functioning, n (%)
Fall incident previous 12 months 127 (64.5) 45 (57.7) 82 (68.9)
Walking difficulties a 143 (73.0) 52 (66.7) 91 (77.1)
Use of walking aid a 108 (55.1) 33 (42.9) 75 (63.0)
Impaired standing balance a
Never 34 (17.4) 10 (12.8) 24 (20.5)
Sometimes 73 (37.4) 33 (42.3) 40 (34.2)
Regularly 57 (29.2) 24 (30.8) 33 (28.2)
Always 31 (15.9) 11 (14.1) 20 (17.1)
Handgrip strength, kg 26.1 (8.2) 33.7 (6.2) 21.1 (4.9)
Knee extension strength, N b 202 (96) 261 (108) 162 (60)
ALM/height², kg/m² b 7.14 (1.20) 7.82 (0.84) 6.63 (1.19)
Lean mass percentage, % b 63.8 (8.9) 69.6 (6.6) 59.6 (7.9)
All parameters are presented as mean with standard deviation unless indicated otherwise. Data available 
in a n=194/195, b n=132, c n=189 and d n=121. # Defined as > 14 units per week for females or > 21 per week 
for males. †Present in outpatients with two or more diseases, including chronic obstructive pulmonary 
diseases, decompensatio cordis, diabetes mellitus, hypertension, malignancy, myocardial infarction, 
Parkinson’s disease, (osteo)arthritis, transient ischemic attack and stroke. ‡Present with a depression 
subscore of >8 on the Hospital Anxiety and Depression Scale. IQR: inter quartile range. MMSE: Mini 
Mental State Examination. SPPB: Short Physical Performance Battery. ALM: appendicular lean mass.
Table 1: Elderly outpatient characteristics. 
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touched the toes of the other. Standing positions were first assessed with eyes open 
as part of the SPPB (23). Subsequently, all standing positions were repeated with eyes 
closed. The elderly outpatients were allowed three trials if standing balance was lost 
prematurely. When the elderly outpatients could not complete a standing position, 
consecutive positions were not performed. Six elderly outpatients did not attempt 
the standing positions with eyes closed due to lack of time or lack of motivation, 
leaving 191 outpatients for analyses of standing balance conditions with eyes closed.
Center of Pressure movement 
All standing conditions were performed on a triangular six degrees of freedom force 
plate (Forcelink B.V., Culemborg, The Netherlands) to measure CoP movement. 
Only successful trials, i.e. completion of 10 seconds of maintaining balance without 
stepping out in case of loss of balance, were considered for further analyses (i.e. 
n=183 were able to maintain balance in side-by-side stance). Because of missing data 
due to technical problems (n=18) and unknown reasons (n=29), CoP movement was 
available in 136 elderly outpatients (in side-by-side stance eyes open). Time series 
of CoP movement in medio-lateral and anterior-posterior direction were used to 
calculate single CoP parameters (24). Direction specific CoP composite scores were 
calculated from standardized single CoP parameters (mean amplitude, amplitude 
variability, mean velocity, velocity variability and range), in anterior-posterior (AP) 
and medial-lateral (ML) direction (25). As age related differences in CoP movement 
are most pronounced in ML direction (25) analyses are shown in ML direction. 
Analyses in AP direction are given in supplementary tables. 
Muscle characteristics
Muscle strength
Handgrip strength was measured using an isometric hand dynamometer (JAMAR 
hand dynamometer, Sammons Preston, Inc., Bolingbrook, IL, USA). Outpatients 
were instructed to maintain an upright standing position with their arms along the 
side, while holding the dynamometer in one hand. The width of the dynamometer’s 
handle was adjusted to hand size such that the middle phalanx rested on the inner 
handle. Three trials were performed alternately for each hand. Outpatients were 
actively encouraged to squeeze with maximal strength. The best performance of all 
trials was used for analyses.
Isometric knee extension strength was measured in a seated position with hips 
and knees in 90 degrees by a force transducer mounted in a chair (Forcelink B.V., 
Culemborg, The Netherlands). Outpatients were asked to push with maximal effort 
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against a cuff positioned just above the talocrural joint. Holding on to the armrest of 
the chair or leaning backward was allowed, but not rising from the seating. This was 
checked by the investigator and corrected if necessary. Three trials were performed 
for each leg. The best performance of all trials was used for analyses. Structural 
measurement of knee extension strength was added to the CGA in May 2011. 
Muscle mass
Body composition was measured using a direct segmental multi-frequency 
bioelectrical impedance analysis (BIA, InBody 720, Biospace Co., Ltd, Seoul, Korea). 
This technique has been shown to be a valid tool for the assessment of whole body 
composition and segmental lean measurements (26). The elderly outpatients wore 
normal indoor clothing and were instructed to stand barefoot on the machine 
platform holding a sensor in each hand. Two formulas were used to represent 
muscle mass. ALM/height2 was calculated as the sum of lean mass in all four limbs 
(appendicular lean mass (ALM)) divided by the height squared (4). Lean mass 
percentage was calculated as total lean mass as percentage of total body mass (27). 
In case of inability to stand on the machine platform without assistance for two 
minutes (n=5), wearing compressive stockings (n=22), having a pacemaker (n=15), 
or unknown reasons (n=14), BIA was not assessed. After exclusion of data due to 
technical problems (n=9) valid BIA data were available in 132 elderly outpatients.
Statistical analyses
Figure 1: Percentage of elderly outpatients able to maintain balance in the different standing 
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Continuous variables with Gaussian distribution are presented as mean and 
standard deviation, otherwise as median and interquartile range or number and 
percentage. All muscle characteristics were standardized into sex-specific z-scores. 
The association between standardized muscle characteristics and the ability to 
maintain standing balance was analyzed using logistic regression with adjustment 
for age. Additional adjustment models included body mass, height, MMSE score 
and multimorbidity. The association between muscle characteristics and CoP 
movement was studied using linear regression with the same adjustment models. 
Statistical analyses were performed using SPSS for Windows (SPSS Inc, Chicago, 
USA), version 20. P values <0.05 were considered statistically significant. 
Results
Elderly outpatient characteristics
The characteristics of elderly outpatients are presented in Table 1. Mean age was 81.9 
years. 64.5 Percent of the elderly outpatients had at least one fall incident in the 12 
months prior to the visit to the outpatient clinic.
Standing balance 
Ability to maintain standing balance
The percentage of elderly outpatients able to maintain balance in different standing 
conditions is shown in Figure 1. In more difficult standing conditions, less elderly 
outpatients were able to maintain standing balance. In the standing positions with 
eyes open 183 elderly outpatients (92.9%) were able to maintain side-by-side stance, 
164 (83.2%) semi-tandem stance and 66 (33.5%) tandem stance. In standing positions 
with eyes closed 152 elderly outpatients (79.6%) were able to maintain side-by-side 
stance, 90 (47.1%) semi-tandem stance and 4 (2.1%) tandem stance. 
Center of Pressure movement
Table 2 shows the CoP movement represented by different CoP parameters used 
for calculating composite scores in anterior-posterior (AP) and medio-lateral (ML) 
direction. CoP parameters were higher in more difficult standing conditions.
Muscle characteristics and standing balance
Muscle strength
The association between muscle strength and the ability to maintain balance in 
different standing conditions is displayed in Table 3. Elderly outpatients with a 
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higher handgrip strength or knee extension strength were significantly more likely 
to be able to maintain standing balance for ten seconds in all standing conditions, 
except for handgrip strength and semi-tandem stance with eyes closed. Further 
adjustments for body mass, height, MMSE score, and multimorbidity, attenuated 
the associations, but overall significance remained.
Handgrip strength and knee extension strength were not associated with CoP 
movement in ML (Table 4) and in AP (Table 5) direction. 
Muscle mass
Table 3 displays the association between muscle mass and the ability to maintain 
standing balance in different standing conditions. There was no association between 
ALM/height2 or lean mass percentage and the ability to maintain standing balance, 
except for a positive association between ALM/height2 and tandem stance with eyes 
open that disappeared in the fully adjusted model.
Both indices of muscle mass, ALM/height2 as well as lean mass percentage, were not 
associated with the CoP movement in ML (Table 4a) and in AP (Table 4b) direction.
Side-by-side Semi-tandem Tandem
AP ML AP ML AP ML
Eyes open (available) (n=136) (n=120) (n=56)
Mean amplitude (cm) 0.56 (0.02) 0.60 (0.02) 0.61 (0.04) 0.72 (0.03) 0.74 (0.04) 0.72 (0.03)
Range (cm) 3.38 (0.11) 3.51 (0.13) 3.88 (0.19) 4.25 (0.18) 4.94 (0.28) 3.92 (0.17)
Mean velocity (cm/s) 5.51 (0.10) 4.09 (0.10) 5.89 (0.13) 4.78 (0.13) 6.85 (0.22) 5.41 (0.21)
Amplitude var (cm) 0.71 (0.02) 0.75 (0.03) 0.77 (0.04) 0.91 (0.04) 0.95 (0.05) 0.88 (0.04)
Velocity var (cm/s) 7.87 (0.14) 5.70 (0.14) 8.41 (0.22) 6.76 (0.23) 9.88 (0.38) 7.55 (0.28)
Eyes closed (available) (n=119) (n=75)
n.a.*
Mean amplitude (cm) 0.74 (0.03) 0.85 (0.03) 0.78 (0.04) 1.03 (0.04)
Range (cm) 4.38 (0.15) 4.86 (0.17) 4.91 (0.25) 5.64 (0.23)
Mean velocity (cm/s) 6.59 (0.15) 5.67 (0.14) 7.24 (0.24) 6.76 (0.26)
Ampltiude var (cm) 0.93 (0.03) 1.06 (0.04) 0.99 (0.05) 1.27 (0.05)
Velocity var (cm/s) 9.09 (0.20) 7.88 (0.20) 10.02 (0.34) 9.33 (0.37)
Data are given in mean and standard error. *Not applicable, number of patients able to maintain the task 
is less than 5. AP = anterior-posterior direction, ML = medio-lateral direction, var=variability.
Table 2: CoP movement, represented by CoP parameters, within elderly outpatients 
able to maintain different standing positions with eyes open and eyes closed in 
anterior-posterior and medio-lateral direction.








Model 1 2.81 1.27-6.21 0.011 1.98 1.23-3.18 0.005 1.58 1.11-2.26 0.012
Model 2 2.17 0.89-5.33 0.09 1.78 1.07-2.95 0.026 1.59 1.09-2.31 0.016
Model 3 2.16 0.85-5.45 0.11 1.69 1.01-2.81 0.046 1.47 1.00-2.16 0.050
Knee extension strength
Model 1 3.87 1.04-14.36 0.043 2.11 1.12-3.99 0.021 1.67 1.11-2.51 0.014
Model 2 5.33 1.14-24.96 0.034 2.38 1.21-4.68 0.012 1.78 1.16-2.74 0.008
Model 3 5.34 1.04-27.33 0.045 2.11 1.06-4.23 0.035 1.76 1.11-2.78 0.016
ALM/height²
Model 1 0.81 0.48-1.35 0.41 1.57 1.04-2.39 0.033
Model 2a 0.64 0.34-1.21 0.17 1.57 1.03-2.41 0.038
Model 3a n.a. 0.65 0.34-1.24 0.19 1.44 0.85-2.46 0.18
Lean mass percentage 
Model 1 1.24 0.69-2.20 0.47 0.96 0.66-1.40 0.82
Model 2b 1.26 0.70-2.26 0.45 0.95 0.65-1.39 0.78




Model 1 1.94 1.24-3.03 0.004 1.11 0.80-1.54 0.54
n.a.
Model 2 2.03 1.26-3.30 0.004 1.17 0.83-1.66 0.37
Model 3 2.00 1.22-3.27 0.006 1.19 0.83-1.71 0.34
Knee extension strength 
Model 1 2.62 1.37-5.03 0.004 1.5 1.01-2.23 0.046
Model 2 3.33 1.61-6.89 0.001 1.72 1.13-2.63 0.012
Model 3 2.95 1.40-6.18 0.004 1.74 1.11-2.73 0.017
ALM/height²
Model 1 0.99 0.60-1.62 0.95 0.87 0.59-1.29 0.50
Model 2a 1.02 0.55-1.89 0.95 0.98 0.59-1.62 0.94
Model 3a 1.00 0.54-1.85 1.00 0.96 0.56-1.64 0.88
Lean mass percentage 
Model 1 1.30 0.77-2.20 0.33 1.16 0.80-1.68 0.44
Model 2b 1.30 0.77-2.19 0.33 1.16 0.80-1.69 0.43
Model 3b 1.41 0.80-2.48 0.23 1.23 0.83-1.83 0.31
All muscle characteristics were standardized in gender-specific Z-scores. Ability to maintain standing 
balance: 0=unable, 1=able. Model 1: adjusted for age, model 2: as model 1 and body mass and height, 
model 3: as model 2 and MMSE score and multimorbidity. a not adjusted for height. b not adjusted for 
body mass. n.a.: not applicable, number of elderly outpatients able or unable to maintain the standing 
condition is less than 5. MMSE: mini mental state examination. ALM: appendicular lean mass.
 Table 3: Association between muscle characteristics and ability to maintain balance 




Muscle strength is positively associated with the ability to maintain standing balance 
in community-dwelling elderly referred to a geriatric outpatient clinic. Muscle mass 
did not associate with the ability to maintain standing balance in most balance 
conditions, although a positive association was found between ALM/height2 and 
tandem stance with eyes open. Muscle strength and muscle mass were not associated 
with quality of balance as measured with CoP movement. This is the first study that 
examines different muscle characteristics in association with the ability to maintain 
standing balance as well as CoP movement during standing balance in a population 
of elderly outpatients without any exclusion criteria. 
When comparing the present study to previous studies, two aspects need to be 
considered. First, no exclusion criteria were applied in the present study, which 
contrasts other studies including healthy elderly. Elderly outpatients are more likely 
to have multimorbidity and deterioration in more than one system involved in 
standing balance (11;17;18). Second, “balance” is inconsistently defined in literature 
for standing (static) and dynamic balance, i.e. not as isolated standing conditions, 
but as the score from SPPB (23), a sum score of the three foot positions (10;20), or as 
different dynamic balance tests as assessed with the Timed Up and Go test, walking 
speed, or chair-stand test (19). It has been shown that standing balance tests are 
different from dynamic balance tests (28;29). Therefore we discuss our results with 
respect to studies that measured standing balance (also called quiet stance, or static 
balance).
To the best of our knowledge, there are no studies describing the association of muscle 
strength with both the ability to maintain standing balance and the CoP movement 
during standing balance in elderly. In line with this study, a positive association 
between muscle strength and the ability to maintain balance has been described 
in healthy elderly (10;11) as well as elderly with mobility difficulties (19;20) aged 
65 years and older. In 985 elderly women with mobility difficulties, those with a 
higher knee extension strength had a higher ability to maintain balance in side-by-
side, semi-tandem, and tandem stance with eyes open (20). The association between 
muscle strength and standing balance was not present in previous studies evaluating 
quality of standing balance by CoP movement in healthy elderly (14-16;28;30). This 
is also in line with our study, as no association was found between muscle strength 
and CoP movement. However, a positive association between muscle strength and 
CoP movement has also been reported in healthy elderly (13) and women with 
osteoporosis (31).
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Table 4a: Association between muscle characteristics and CoP movement in medio-
lateral direction in different standing positions with eyes open and eyes closed.
Side-by-side Semi-tandem Tandem
Beta SE P Beta SE P Beta SE P
Eyes open (available) (n=136) (n=120) (n=56)
Handgrip strength 
Model 1 −0.08 0.08 0.33 0.02 0.09 0.86 −0.09 0.13 0.52
Model 2 −0.10 0.09 0.23 −0.03 0.09 0.78 −0.15 0.14 0.27
Model 3 -0.09 0.09 0.34 −0.03 0.10 0.78 −0.14 0.15 0.33
Knee extension strength 
Model 1 −0.02 0.08 0.77 0.03 0.07 0.64 0.04 0.14 0.78
Model 2 −0.01 0.09 0.92 0.07 0.07 0.31 0.01 0.14 0.95
Model 3 0.01 0.09 0.88 0.07 0.08 0.35 0.02 0.15 0.88
ALM/height²
Model 1 0.06 0.09 0.54 -0.04 0.12 0.75 -0.12 0.12 0.30
Model 2a 0.06 0.12 0.64 -0.17 0.17 0.31 -0.25 0.16 0.14
Model 3a 0.10 0.12 0.42 -0.17 0.18 0.34 -0.19 0.17 0.28
Lean mass percentage
Model 1 0.09 0.09 0.33 0.01 0.10 0.96 -0.06 0.10 0.55
Model 2b 0.07 0.09 0.45 -0.03 0.10 0.78 -0.09 0.11 0.41
Model 3b 0.10 0.10 0.31 -0.04 0.11 0.74 -0.07 0.11 0.51
Eyes closed (available) (n=119) (n=75)
Handgrip strength
n.a.
Model 1 0.09 0.08 0.30 0.10 0.10 0.32
Model 2 0.06 0.08 0.46 0.08 0.11 0.47
Model 3 0.05 0.09 0.55 0.05 0.12 0.67
Knee extension strength 
Model 1 0.14 0.10 0.15 0.23 0.12 0.06
Model 2 0.17 0.10 0.08 0.27 0.13 0.033
Model 3 0.14 0.10 0.16 0.17 0.14 0.23
ALM/height²
Model 1 0.06 0.11 0.60 0.04 0.17 0.82
Model 2a -0.10 0.15 0.53 -0.04 0.25 0.88
Model 3a -0.07 0.15 0.65 0.06 0.27 0.81
Lean mass percentage
Model 1 -0.02 0.09 0.80 0.11 0.13 0.43
Model 2b -0.06 0.09 0.53 0.04 0.13 0.78
Model 3b -0.10 0.09 0.28 0.03 0.15 0.85
(Table legend for Table 4a and 4b) All muscle characteristics were standardized in gender-specific 
Z-scores. Model 1: adjusted for age, model 2: as model 1 and body mass and height, model 3: as model 2 




Beta SE P Beta SE P Beta SE P
Eyes open (available) (n=136) (n=120) (n=56)
Handgrip strength 
Model 1 0.04 0.08 0.62 0.05 0.08 0.58 0.03 0.12 0.81
Model 2 0.07 0.08 0.37 0.002 0.09 0.98 −0.01 0.13 0.96
Model 3 0.07 0.08 0.37 −0.01 0.09 0.93 −0.05 0.14 0.70
Knee extension strength 
Model 1 0.05 0.08 0.48 −0.01 0.07 0.91 −0.06 0.14 0.69
Model 2 0.11 0.08 0.18 0.02 0.07 0.76 −0.08 0.15 0.63
Model 3 0.13 0.08 0.11 0.02 0.07 0.75 -0.06 0.16 0.73
ALM/height²
Model 1 -0.18 0.09 0.04 0.03 0.11 0.80 -0.19 0.12 0.11
Model 2a -0.18 0.11 0.11 -0.12 0.16 0.45 -0.23 0.17 0.18
Model 3a -0.15 0.11 0.19 -0.11 0.16 0.50 -0.22 0.18 0.22
Lean mass percentage
Model 1 0.10 0.08 0.24 0.00 0.09 0.96 -0.03 0.11 0.82
Model 2b 0.09 0.09 0.28 -0.02 0.10 0.80 -0.04 0.11 0.75
Model 3b 0.14 0.09 0.14 -0.02 0.10 0.85 -0.04 0.12 0.75
Eyes closed (available) (n=119) (n=75)
Handgrip strength
n.a.*
Model 1 0.06 0.08 0.45 −0.11 0.10 0.28
Model 2 0.05 0.08 0.54 −0.14 0.10 0.17
Model 3 0.05 0.08 0.57 -0.18 0.11 0.11
Knee extension strength 
Model 1 0.11 0.09 0.21 0.04 0.12 0.74
Model 2 0.17 0.09 0.06 0.07 0.13 0.57
Model 3 0.15 0.09 0.12 0.01 0.14 0.93
ALM/height²
Model 1 -0.05 0.11 0.68 0.22 0.15 0.16
Model 2a -0.14 0.14 0.32 -0.42 0.23 0.08
Model 3a -0.08 0.15 0.61 -0.31 0.25 0.23
Lean mass percentage
Model 1 0.02 0.09 0.87 0.02 0.13 0.89
Model 2b -0.01 0.09 0.93 -0.04 0.13 0.76
Model 3b 0.00 0.09 1.00 -0.02 0.14 0.91
Table 4b: Association between muscle characteristics and CoP movement in anterior-
posterior direction in different standing positions with eyes open and eyes closed. 
(continued from Table legend 4a) mass. n.a.: not applicable, number of elderly outpatients able to maintain 
the balance condition is less than 5. ALM: appendicular lean mass.
Muscle strength rather than muscle mass is associated with standing balance 
137
8
No association between measures of muscle mass and the ability to maintain standing 
balance was found in the present study. A limited number of studies describe the 
association between muscle mass and ability to maintain standing balance (12;27). A 
positive association has been described between quadriceps muscle mass and one-leg 
standing time in healthy elderly (12). Furthermore, Janssen et al. reported a positive 
association between lean mass percentage and the ability to maintain balance in 
tandem stance in males aged over 60 years (27). Previous research on the association 
between muscle mass and CoP movement is limited, reporting a positive association 
for quadriceps muscle mass (12), and no association for lean mass divided by height 
squared (14).
The fact that in the current study muscle strength was found to be associated with 
the ability to maintain standing balance rather than muscle mass, is explained by 
the differences between the characteristics “muscle strength” and “muscle mass”. 
Muscle strength appears to decline more with age than muscle mass (32-35). Other 
factors in addition to muscle mass are important to generate muscle strength such as 
neural control, cognition, cardiovascular and joint function (35). Furthermore, due 
to pain muscle strength may be underestimated (36;37). Muscle tissue is not only a 
force generator, but has an important function as an internal organ, i.e. involved in 
glucose metabolism (38;39). Maintenance of standing balance obviously reflects the 
role of muscle as a strength generator (35;40). In this respect, this article provides 
further evidence to include assessment of muscle strength in clinical practice (41-43).
A possible explanation for the absence of an association between muscle 
characteristics and CoP movement could be selection of the fittest. CoP movement 
could only be assessed in outpatients who completed the standing balance 
conditions. Another explanation is large heterogeneity among elderly outpatients: 
the presence of multimorbidity and the deterioration of multiple systems involved 
in standing balance, i.e. sensory systems and neural control may interfere with 
the association between muscle characteristics and CoP movement (11;17;18). For 
instance, in patients with an intact sensory system and neural control, a higher 
muscle mass or strength may be associated with low CoP movement. In patients 
with deterioration of the sensory or neural system, high muscle strength could 
also be the result of repetitive use of muscles as compensatory strategy. For these 
patients, higher muscle mass or strength would therefore be associated with higher 
CoP movement. A decline of distinct systems and compensatory strategies can result 
in comparable CoP movement (44). In fact, lower CoP movement may not be related 
to better quality of standing balance, despite previously described differences in 
CoP movement between young and old adults (25).
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The question arises whether an increase in muscle strength does improve standing 
balance in elderly outpatients. Physical exercise and training programmes have been 
shown to be beneficial in elderly, as they lead to an increase of muscle mass, muscle 
strength and even neuromuscular activity (45;46), although not all trials show a 
positive effect (47). Suppletion of hormones (48), vitamin D, or nutrients (46;49) 
may increase or prevent further decrease of muscle mass and strength. However, 
evidence is still very weak, as large scale placebo controlled intervention studies 
for long term effects of interventions are missing. Regarding strength training, a 
systematic review of randomized controlled trials including elderly showed a 
positive effect of resistance training to improve balance in 18 of 33 randomized 
controlled trials. These studies included a range of methods (static and dynamic) to 
measure ‘balance’ (50). Two of these randomized controlled trials included elderly 
with mobility difficulties (51;52): one trial found an improved balance after training 
in a small number of elderly in the intervention group (51), and one trial found no 
effect on balance (52). 
Strength of this study was the combined analyses of both muscle strength and 
muscle mass with the ability to maintain standing balance and CoP movement. The 
population of elderly outpatients is unique as there were no exclusion criteria. By 
assessing the ability to maintain standing balance in elderly outpatients, results of 
this study will be highly relevant in clinical practice. The heterogeneity of the study 
population implies that larger numbers of outpatients need to be assessed to relate 
outcome measures to function of specific systems involved in standing balance, i.e. 
sensory systems and neural control. Another limitation is the cross-sectional design, 
which prevents assessments causal inference.
Conclusion
Muscle strength rather than muscle mass is associated with the ability to maintain 
standing balance in community-dwelling elderly referred to a geriatric outpatient 
clinic. This indicates the additional value of assessment of muscle strength in clinical 
practice. Improvement of muscle strength is a target for potential intervention 
for impaired standing balance in this population of elderly outpatients with 
multimorbidity.
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Sarcopenia has been associated with a higher mortality, poor physical functioning, 
poor outcome of surgery and higher drug toxicity (1-4). Despite increasing 
knowledge on the clinical implications of sarcopenia, there is no general consensus 
on the definition of sarcopenia. 
To diagnose sarcopenia in clinical practice a clear definition for sarcopenia is needed. 
Since the coining of the term ‘sarcopenia’ in 1989, many different diagnostic criteria 
have been suggested to establish a clinically applicable definition (5). The aim of 
the research presented in this thesis was to assess the implications of the use of 
different diagnostic criteria for sarcopenia, and to define the most accurate criteria 
for sarcopenia.
This chapter summarizes the key findings presented in this thesis, reflects on 
differences between diagnostic criteria for sarcopenia, and includes recommendations 
for the definition of sarcopenia and future research.
Diagnostic criteria for sarcopenia
Diagnostic criteria for sarcopenia that are being used in literature can be divided 
into criteria based on (1) low muscle mass (1;6), (2) low muscle strength (7), and (3) 
low walking speed (8;9). It is important to note that most of these diagnostic criteria 
include cut-off points based on ‘low muscle mass‘, and not ‘loss of muscle mass’. In 
this thesis it was shown that criteria based on low muscle mass can be further divided 
into relative muscle mass and absolute muscle mass. Lean mass as measured with 
bioimpedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) was used 
as an estimate of muscle mass. Absolute muscle mass was defined as the unadjusted 
total amount of lean mass in kilograms, or as the appendicular lean mass divided by 
height squared (ALM/height2) (1). Although the formula ALM/height2 corrects for 
body height, we considered ALM/height2 to be an absolute measure of muscle mass, 
as results in Chapters five to eight show the importance of adjusting for fat mass 
or body mass. Relative muscle mass was defined as the amount of muscle mass as 
percentage of total body mass (lean mass percentage or ALM percentage) (10).
In Chapter four it was shown that the prevalence of sarcopenia in middle-aged to 
older adults from the Leiden Longevity Study (LLS) varied widely depending on 
which diagnostic criteria and cut-off points were used. Criteria based on low grip 
strength and absolute muscle mass failed to match with criteria based on relative 
muscle mass. Therefore, the presence of sarcopenia in participants was highly 
dependent on the used criteria. This indicates that the variance in prevalence of 
sarcopenia ranging from 7 to 40 percent between cohorts could be at least partially 
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explained by the use of different diagnostic criteria (11). Consequently, concerns 
were raised about the validity of comparison between studies using different criteria 
to diagnose sarcopenia.
Sarcopenia and muscle related outcome
Muscle tissue is important in the generation of force and in physical performance 
(1;6;12). In addition, muscle tissue is an important internal organ involved in protein 
storage, glucose regulation, hormonal homeostasis and cellular communication 
(4;13;14). Finally, muscle tissue can stimulate bone formation, by mechanical stress 
exerted on bones (15;16). In this thesis, diagnostic criteria for sarcopenia were 
compared in their association with these different aspects of muscle related clinical 
outcome. 
Association of diagnostic criteria for sarcopenia with physical performance
In chapter five, we compared the predictive value of relative and absolute muscle 
mass and muscle strength with respect to physical performance: walking speed, 
Timed Up and Go test (TUG) and physical fitness as estimated with the Astrand-
Rhyming test. In old participants of the MYOAGE study, relative muscle mass was 
the only diagnostic criterium for sarcopenia associated with all the tested parameters 
of physical performance: walking speed, TUG, and physical fitness. Contrarily, 
absolute muscle mass was not associated with physical performance. Knee extension 
torque and handgrip strength were associated with a faster walking speed. Knee 
extension torque was associated with TUG. Handgrip strength was not associated 
with TUG. Knee extension torque and handgrip strength were not associated with 
physical fitness. In young participants of the MYOAGE study, diagnostic criteria 
for sarcopenia were not associated with physical performance, except for a positive 
association between relative muscle mass and physical fitness. We concluded that 
relative muscle mass was most associated with physical performance, whereas 
absolute muscle mass was not associated with physical performance. Diagnostic 
criteria for sarcopenia cannot be used interchangeably in the association with 
physical performance.
Association of diagnostic criteria for sarcopenia with glucose regulation
In Chapter six we compared the association between different diagnostic criteria 
for sarcopenia and valid measures of insulin resistance derived from an oral 
glucose tolerance test (OGTT). Measures of insulin resistance were: area under the 
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curve (AUC) insulin, AUC glucose, and homeostasis model assessment for insulin 
resistance (HOMA-IR). In middle aged and older non-diabetic males and females 
from the MYOAGE study and LLS, relative muscle mass was inversely associated 
with OGTT derived measures of insulin resistance. Contrarily, absolute muscle 
mass was positively associated with AUC insulin and HOMA-IR, and not associated 
with AUC glucose. This association appeared to be influenced by the amount of 
fat mass. Handgrip strength was not associated with OGTT derived measures of 
insulin resistance. Walking speed was only associated with AUC insulin in males. 
We concluded that the role of muscle tissue as an internal glucose regulating organ is 
better reflected by relative muscle mass than by muscle strength or walking speed.
Association of diagnostic criteria for sarcopenia with bone mineral density
In Chapter seven we compared diagnostic criteria for sarcopenia with respect to their 
association with BMD in healthy young and old men and women of the MYOAGE 
study. Besides, we investigated whether muscle mass or fat mass as components of 
body mass were most strongly associated with BMD. Absolute muscle mass was most 
strongly positively associated with BMD in all subgroups. Relative muscle mass was 
inversely associated with BMD in old women, and not significantly associated with 
BMD in other subgroups. This association in old women appeared to be influenced 
by the total body mass. Muscle strength was associated with whole body BMD in 
young participants and older men, but not in old women. Walking speed and TUG 
were not associated with BMD.
Association of diagnostic criteria for sarcopenia with standing balance
In Chapter eight we compared muscle mass and muscle strength with respect to 
their association with standing balance in community-dwelling elderly referred 
to a geriatric outpatient clinic. Standing balance was measured with the ability 
to maintain balance during ten seconds in different balance conditions, and with 
the quality of balance during these conditions, measured as the movement of the 
center of pressure. Handgrip and knee extension strength were positively related 
to the ability to maintain balance with eyes open in side-by-side, semi-tandem, and 
tandem stance, and with eyes closed in side-by-side and semi-tandem stance (knee 
extension strength only). Relative and absolute muscle mass were not associated 
with the ability to maintain standing balance, except for an association between 
absolute muscle mass and tandem stance with eyes open that disappeared in the 
fully adjusted model. Muscle mass and muscle strength were not associated with 





In Chapters four to eight, obvious differences between muscle mass and muscle 
strength were observed. Previously it has been shown that muscle strength declines 
much more with age than absolute muscle mass (17). An explanation for differences, 
is that other factors in addition to muscle mass are important to generate muscle 
strength such as neural control, cognition, cardiovascular and joint function (18). 
These factors are also known to deteriorate with increasing age (19;20). It is shown 
that muscle strength is more predictive than muscle mass of certain outcome 
parameters such as disability (21) or mortality (22). Therefore, it has been suggested to 
differentiate between the terms ‘sarcopenia’ for a low muscle mass, and ‘dynapenia’ 
for a low muscle strength (18;23). Others argue against the separation of the terms 
sarcopenia and dynapenia due to risk of nomenclature introducing confusion (24). 
This thesis underlines that sarcopenia and dynapenia have different implications 
in old age. It appears that the predictive value of sarcopenia and dynapenia is 
dependent on the muscle related outcome of interest. If neural control is involved 
in the muscle related outcome of interest, as is the case with standing balance, this 
outcome is probably better predicted by muscle strength as neural control is also 
needed to generate strength. If the functioning of muscle tissue as an internal organ is 
evaluated, as is the case with insulin resistance, the muscle related outcome is better 
predicted by muscle mass. On the other hand, relative muscle mass was predictive 
of Timed Up and Go test and walking speed which also requires neural control. 
The characteristics of the study population may also affect the predictive value of 
sarcopenia and dynapenia. The geriatric outpatient population studied in Chapter 
eight is more frail as compared to the relatively healthy MYOAGE older adults. In 
the more frail elderly, muscle strength was lower and therefore more likely below 
the threshold needed for safe standing and walking. In the healthy older adults from 
the MYOAGE study it is possible that the age-related decline in muscle strength is 
not yet below the threshold for impact on muscle related outcome such as the ability 
to maintain balance. Future research is needed to explore whether relative muscle 
mass has the same predictive value for physical performance, glucose regulation, 
and bone mineral density in more frail elderly as it has in healthy older adults.
Because of the differences between muscle mass and muscle strength, it is suggested 
to use the term sarcopenia for low muscle mass only, and dynapenia for a low muscle 
strength.
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Consensus groups on sarcopenia, walking speed and frailty
The need for a consensus definition for sarcopenia has been recognized before. Several 
consensus groups have been established to reach consensus for defining sarcopenia. 
Currently it is suggested to use walking speed as diagnostic criterion for sarcopenia, 
combined with a low muscle mass or muscle strength (8;9). Walking speed has been 
shown a good predictor of mortality (24), overall health and functional status (25). 
This is an argument to measure walking speed in clinical practice as a predictor of 
general health. However, reservations can be expressed about the use of walking 
speed to detect sarcopenia. Walking speed is not dependent on muscle tissue only, 
but also requires the functioning of other systems. Furthermore, walking speed has 
also been used in diagnostic criteria for frailty, which makes the distinction between 
frailty and sarcopenia less clear (26). Besides, in frail elderly who are unable to walk, 
walking speed cannot be measured. In this thesis, walking speed was not predictive of 
the multiple functions of muscle tissue, and therefore not an appropriate diagnostic 
criterion to define sarcopenia. 
Despite the effort of consensus working groups, there is no unanimous agreement 
on the definition for sarcopenia, so that different definitions still co-exist in scientific 
literature.
Relative muscle mass versus absolute muscle mass
In Chapters six and seven the association between muscle mass and insulin 
resistance and BMD respectively, was in the opposite direction for relative muscle 
mass as compared to absolute muscle mass. This indicates that relative and absolute 
muscle mass are different characteristics. In order to visualize differences between 
relative and absolute muscle mass, body mass and fat mass, we combined DXA 
and BIA data from the MYOAGE study, the Leiden Longevity study and elderly 
outpatients, described in detail in this thesis. This analysis shows a poor correlation 
between relative and absolute muscle mass (figure 1). This poor correlation may 
be explained by differences between relative and absolute muscle mass in their 
correlation with body mass (figure 2) and fat mass (figure 3). A higher body or fat 
mass is correlated with a lower relative muscle mass but with a higher absolute 
muscle mass. Differences between relative and absolute muscle mass have been 
described before (10). In line with the correlations presented in figure 2 and 3, a 
higher body mass index was associated with a lower relative muscle mass but with 
a higher absolute muscle mass (10).
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Role of fat mass or body mass on muscle related outcome
Studying the association between relative muscle mass with muscle related outcome 
such as insulin resistance, the question arises whether observed associations are 
caused by muscle mass or by fat mass. A change in muscle mass at older age is often 
associated with a change in fat mass (10;12). The inverse relation of relative muscle 
mass but not absolute muscle mass with insulin resistance can be explained by the 
effect of fat mass. The positive relation between absolute muscle mass and measures 
of insulin resistance attenuated after adjustment for fat mass in this study. Adjusting 
muscle mass for height only, as was first suggested by Baumgartner (1) seems to be 
insufficient to account for the influence of fat mass. Fat secreted adipokines and the 
recently described muscle secreted myokines appear to be involved in the cross-talk 
between fat mass and skeletal muscle mass (27;28).
The association between absolute muscle mass and muscle-related outcome is highly 
Figure 1: Scatterplots with fit line for the correlation between absolute muscle mass 
(appendicular lean mass divided by height squared) and relative muscle mass (appendicular 
lean mass as percentage of body mass). Preliminary analyses in young and old adults from 
the MYOAGE study, the LLS, and elderly outpatients. Colors represent the different study 
cohorts and age categories.
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influenced by fat mass, as is shown in Chapters four to seven. These examples 
illustrate that fat mass or body mass are important confounders when assessing the 
role of muscle mass.
 
Cut-off points and reference populations
Next to differences between relative and absolute muscle mass, the diagnosis of 
sarcopenia depends on reference populations and cut-off points. Ideally, the amount 
of muscle mass in an elderly patient is compared with the amount of muscle mass 
during the patient’s own adult life, to measure ‘loss of’ muscle mass. In the absence 
of previous measurements of muscle mass, cut-off points for sarcopenia have been 
suggested for assessment of muscle mass on an individual level in clinical practice. 
In chapter four it was shown that cut-off points for sarcopenia have been based 
on two standard deviations below a young reference populations mean (1), the 
lowest percentile in an elderly population (29), or from the association with low 
physical functioning (7;30). Differences in reference populations may be caused by 
age, ethnicity, genetic background and environmental factors such as the level of 
physical activity. Besides deciding on which diagnostic criteria for sarcopenia to use, 
it is important to agree on reference populations that can be used in specific ethnic 
groups. Establishing reference databases generally requires a large sample size to 
achieve reliable results. Furthermore, it remains important to invest in longitudinal 
studies including the general population. Assessing the relation between muscle 
mass and muscle related outcome in these studies, helps to establish possible critical 
thresholds of muscle mass needed for muscle function.
Clinical implications
Currently the presence of sarcopenia is not always recognized in clinical practice. 
Results presented in this thesis contribute to understand the importance of clinical 
recognition of sarcopenia. We have shown that muscle mass is not only related to 
physical performance, but also to glucose regulation and bone mineral density. By 
reviewing the literature we found an association of sarcopenia with increased drug 
toxicity and poor outcome after surgery (Chapter two). This should be taken into 
account in clinical practice when sarcopenia is recognized.
Final implementation of the term sarcopenia is difficult in the absence of a generally 
accepted definition for sarcopenia, but currently used cut-off points could contribute 
to clinical judgement when sarcopenia is suspected (Table 1, Chapter two). Physical 
exercise and training programmes have been shown to be of benefit to elderly, as they 
lead to an increase of muscle mass, muscle strength and even neuromuscular activity 
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Figure 2: Scatterplots with fit lines for the correlation between (A) relative muscle mass 
(appendicular lean mass as percentage of body mass) and body mass; and (B) absolute muscle 
mass (appendicular lean mass divided by height squared) and body mass. Symbols represent 
the different study cohorts: young (18-30 y) and old adults (69-81 y) from the MYOAGE 
study, the Leiden Longevity Study (mean age 63 y), and elderly outpatients (mean age 82 y). 
A.
B.
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Figure 3: Scatterplots with fit lines for the correlation between (A) relative muscle mass 
(appendicular lean mass as percentage of body mass) and fat mass; and (B) absolute muscle 
mass (appendicular lean mass divided by height squared) and fat mass. Symbols represent 
the different study cohorts: young (18-30 y) and old adults (69-81 y) from the MYOAGE 





(19;31), although not all trials have been successful (32). Furthermore, suppletion of 
hormones (33), vitamin D or nutrients (31;34) may be helpful to increase or prevent 
further decrease of muscle mass. However, evidence is still very weak, as large scale 
placebo controlled intervention studies for long term effects are missing.
General conclusions and future research
The first aim of this thesis was to assess the implication of the use of different 
diagnostic criteria for sarcopenia. Currently used diagnostic criteria for sarcopenia 
consist of relative or absolute muscle mass, muscle strength, and walking speed. It is 
important to note that most of these diagnostic criteria include cut-off points based on 
‘low muscle mass‘, and not ‘loss of muscle mass’. Results from this thesis contribute 
to the understanding that these diagnostic criteria cannot be used interchangeably 
in the definition of sarcopenia. The use of different diagnostic criteria for sarcopenia 
leads to confusion and poor understanding of what is described. It is impossible to 
compare studies on sarcopenia when different diagnostic criteria are used to define 
sarcopenia. 
The second aim of this thesis was to define the most accurate criteria for sarcopenia. 
Despite the work presented in this thesis, it remains difficult to be conclusive on the 
most accurate criteria. However, recommendations can be given. To avoid confusion, 
the term sarcopenia should be reserved for a low muscle mass and dynapenia for 
a low muscle strength. Comparing sarcopenia and dynapenia, dynapenia is more 
predictive of muscle related outcome where neural control is important, i.e. for 
standing balance. Sarcopenia is better associated with muscle related outcome 
that reflects muscle tissue as an internal organ such as insulin resistance. Defining 
sarcopenia as ‘low muscle mass’ is not specific enough, as results presented in this 
thesis show that there is an important difference between relative muscle mass and 
absolute muscle mass. Absolute muscle mass defined as ALM/height2 is highly 
dependent on fat mass or body mass and not a good predictor of insulin resistance 
or physical performance. There was a positive association between absolute muscle 
mass and BMD, probably because of the weight-bearing effect on bone. Relative 
muscle mass defined as ALM or lean mass as percentage of body mass is a good 
predictor of insulin resistance and physical performance, but the disadvantage is 
that it is difficult to conclude if associations are due to a higher relative muscle mass 
or due to a lower relative fat mass, even after adjustments for fat mass. Based on 
results presented in this thesis it is recommended to use relative muscle mass as 
diagnostic criterion for sarcopenia.
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Future research is needed to assess if sarcopenia is simply a marker for health and 
underlying disease, or a cause of poor outcome. There is a need for studies aimed 
to improve muscle mass in a randomized controlled way, including muscle related 
outcome as endpoint. Furthermore, studies are needed to explore whether drug 
dosage based on muscle mass leads to less drug toxicity when compared to drug 
dosage based on body surface area in geriatric oncology. 
Knowledge on clinical consequences of sarcopenia and meaningful cut-off points 
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Het aantal ouderen is de laatste jaren flink toegenomen en de levensverwachting 
stijgt nog steeds in de Westerse samenleving. In de afgelopen 40 jaar is het aantal 
mensen boven de 65 jaar verdubbeld, met bijna 2,6 miljoen ouderen in 2011 in 
Nederland (1). Met het toenemen van de leeftijd is de vraag hoe wij gezond oud 
kunnen worden zeer actueel. Gezond oud worden, betekent niet alleen het uitblijven 
van een ernstige ziekte, maar ook het zelfstandig kunnen blijven functioneren. Uit 
onderzoek is gebleken dat de hoeveelheid spiermassa na het 50ste levensjaar afneemt 
met ongeveer 1 à 2 procent per jaar (2). Verlies van spiermassa en spierkracht kan het 
vermogen zelfstandig te functioneren bedreigen. Ook kan de functie van de spier als 
intern orgaan veranderen.
In 1989 is de term sarcopenie geïntroduceerd om een gebrek aan spiermassa op 
oudere leeftijd te beschrijven (3). Momenteel zijn er veel verschillende diagnostische 
criteria voor sarcopenie die in de literatuur worden beschreven (4-9). Hierdoor is het 
onduidelijk welke diagnostische criteria gebruikt dienen te worden om sarcopenie 
in de wetenschap of in de praktijk vast te stellen.
In dit proefschrift wordt onderzocht wat de consequenties zijn van het hanteren van 
verschillende diagnostische criteria voor sarcopenie. Het uiteindelijke doel is het 
vinden van de beste definitie voor sarcopenie.
De spier als multifunctioneel orgaan
Hoofdstuk twee geeft een overzicht van de huidige literatuur over een aantal 
aspecten van sarcopenie. Hieruit blijkt de multifunctionaliteit van de spier als orgaan. 
De spier is behalve krachtsleverancier, betrokken bij eiwitopslag, glucoseregulatie, 
hormoonhuishouding en cellulaire communicatie (2). Een lage spiermassa is 
gerelateerd aan een hogere kans op sterfte, afhankelijkheid in dagelijks functioneren, 
bijwerkingen van chemotherapie en ouderdomssuikerziekte (4;6;10-12). Ook bij 
een zeer actieve leefstijl kan sarcopenie optreden door systemische, cellulaire en 
neuromechanische factoren.
Sarcopenie in vergelijking met osteoporose
Sarcopenie is niet het enige begrip binnen de ouderengeneeskunde met discussie over 
de definitie. Voor de leeftijdsgerelateerde ziekte osteoporose (‘botontkalking’) dateert 
deze discussie al van 1940, toen de eerste medische definitie voor osteoporose werd 
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beschreven. De term osteoporose bestond toen al ruim honderd jaar. Om te kunnen 
leren van deze oude discussie vergeleken wij het proces voor het tot stand komen 
van een definitie voor osteoporose met sarcopenie in Hoofstuk drie. Een aantal 
mijlpalen is geïdentificeerd voor het ontwikkelen van een universeel geaccepteerde 
definitie voor osteoporose. Voor sarcopenie zijn de eerste stappen reeds genomen, te 
weten het ontstaan van de term sarcopenie, het vormen van criteria om sarcopenie 
vast te stellen en het begrijpen van de consequenties van sarcopenie. Resterende 
stappen voor het vormen van een algemeen gebruikte definitie van sarcopenie zijn 
specifieke behandelingsmogelijkheden, interesse van de farmaceutisch industrie en 
publieke kenbaarheid.
Studie populaties
MYOAGE Studie Een deel van het onderzoek beschreven in dit proefschrift maakt 
gebruik van gegevens van deelnemers aan de MYOAGE studie. Binnen het Europese 
onderzoeksproject “MYOAGE” wordt onderzoek gedaan naar de mechanismen van 
spierveroudering. In Nederland, Engeland, Finland, Estland en Frankrijk zijn in 
totaal 462 deelnemers geïncludeerd, bestaande uit jongeren (18 to 30 jaar oud) en 
ouderen (69 tot 81 jaar oud). De ouderen werden geselecteerd op het hebben van een 
goede gezondheid, en onderverdeeld in twee groepen op basis van een lager of juist 
hoger activiteitenniveau. Deelnemers aan deze studie bezochten het studiecentrum 
in Leiden.
Leiden Langleven Studie In de Leiden Langleven Studie (LLS) werden 420 families 
geïncludeerd bestaande uit langlevende Kaukasische broers en zussen samen met 
de kinderen en de partners van hun kinderen. In dit proefschrift worden gegevens 
beschreven van de kinderen en hun partners van middelbare tot oudere leeftijd, bij 
wie de spiermassa is gemeten (n=654). Deelnemers aan deze studie bezochten het 
studiecentrum in Leiden.
Patiënten van de geriatrische polikliniek In de periode tussen maart 2011 en januari 2012 
zijn 207 patiënten van de geriatrische polikliniek in het Bronovo Ziekenhuis te Den 
Haag onderzocht middels een standaard geriatrische analyse.
Verschillende diagnostische criteria voor sarcopenie
Sarcopenie blijft vaak onopgemerkt, omdat de afnemende spiermassa wordt 
opgevuld door vet en bindweefsel. Spiermassa kan worden gemeten met dual-energy 
X-rayabsorptiometry (DEXA) of bioimpedantie analyse (BIA)(13). Spierkracht kan 
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worden bepaald door het meten van de handknijpkracht als proxy voor algehele 
spierkracht.
Diagnostische criteria voor sarcopenie die momenteel gebruikt worden kunnen 
grofweg worden ingedeeld in drie categorieën: een lage spiermassa, een lage 
spierkracht, of een lage loopsnelheid. Uit dit proefschrift blijkt dat de spiermassa 
kan worden onderverdeeld in een absolute spiermassa en een relatieve spiermassa, 
afhankelijk van gebruikte correctiefactoren (zie Hoofdstuk 1, Figuur 1). Daarnaast 
worden verschillende afkappunten beschreven waarbij sarcopenie vastgesteld kan 
worden.
Het gebruik van verschillende diagnostische criteria om sarcopenie vast te stellen 
heeft grote gevolgen. In Hoofdstuk vier onderzochten wij de invloed van het gebruik 
van verschillende diagnostische criteria, op het vóórkomen van sarcopenie in de LLS. 
Het vóórkomen van sarcopenie was sterk afhankelijk van het gebruikte criterium. 
Dit betekent dat studies gebaseerd op verschillende criteria voor sarcopenie niet te 
vergelijken zijn.
Sarcopenie als voorspeller van spier-gerelateerde uitkomstmaten
Om vast te kunnen stellen welke diagnostische criteria voor sarcopenie het meest 
voorspellend zijn voor spier-gerelateerde uitkomstmaten, vergelijken wij deze 
criteria in hoofdstuk vijf tot en met acht. 
Sarcopenie als voorspeller van fysiek functioneren
In Hoofdstuk vijf vergelijken wij de relatieve en absolute spiermassa en spierkracht 
voor wat betreft de voorspellende waarde van fysiek functioneren bij deelnemers 
van MYOAGE. Fysiek functioneren werd bepaald met een test voor de loopsnelheid, 
opstaan uit een stoel en afleggen van een parcours (TUG) en een fitness test. Bij 
oudere deelnemers bleek alleen een hogere relatieve spiermassa een voorspeller 
te zijn van beter functioneren op alle drie de testen. In tegenstelling tot relatieve 
spiermassa, was absolute spiermassa niet geassocieerd met de testen van fysiek 
functioneren. Oudere deelnemers met een hogere spierkracht hadden een hogere 
loopsnelheid en betere prestatie op de TUG, maar dezelfde prestatie op de fitness 
test in vergelijking met deelnemers met een lagere spierkracht. Uit deze resultaten 
hebben wij de conclusie getrokken dat relatieve spiermassa het meest voorspellend 
is voor fysiek functioneren.
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Sarcopenie als voorspeller van insulineresistentie
In Hoofdstuk zes vergelijken wij de diagnostische criteria voor sarcopenie als 
voorspeller van insulineresistentie in deelnemers van de MYOAGE studie en de 
LangLeven Studie. Insuline is een hormoon dat zorgt voor de opname van suiker 
(glucose) in de spieren. Bij ouderdomssuikerziekte is er sprake van een verminderde 
gevoeligheid van de spier voor insuline (insulineresistentie). Er is dan meer insuline 
nodig om dezelfde hoeveelheid suiker op te nemen. Bij deelnemers met een lage 
relatieve spiermassa werd vaker een verminderde opname van suiker gezien, wat 
betekent dat er sprake is van meer insulineresistentie. Dit verband werd niet gezien 
bij andere diagnostische criteria voor sarcopenie. Er werd zelfs een tegengesteld 
effect gevonden in het verband tussen absolute spiermassa en insulineresistentie. 
Uit deze resultaten hebben wij de conclusie getrokken dat relatieve spiermassa het 
meest voorspellend is voor insulineresistentie.
Sarcopenie als voorspeller van botdichtheid
Een lage botdichtheid op oudere leeftijd (osteoporose) geeft een hogere kans op 
botbreuken. Op oudere leeftijd heeft een hoger lichaamsgewicht een beschermend 
effect op de botdichtheid. Dit komt waarschijnlijk doordat meer bot wordt aangemaakt 
als het bot meer belast wordt door het hogere lichaamsgewicht. In Hoofdstuk 
zeven vergelijken wij de diagnostische criteria voor sarcopenie als voorspeller voor 
botdichtheid in gezonde jongere en oudere mannen en vrouwen in de MYOAGE 
studie. Het blijkt dat vooral de absolute spiermassa een positieve voorspeller is van 
botdichtheid. Hoe meer absolute spiermassa, hoe sterker de botten, zowel op jonge 
als op oude leeftijd. Relatieve spiermassa was juist een negatieve voorspeller van 
botdichtheid in oudere vrouwen. Jonge mannen en vrouwen en oudere mannen 
met een hogere spierkracht hadden ook een hogere botdichtheid; dit effect was 
niet aanwezig in vrouwen. Loopsnelheid en TUG waren geen voorspellers van 
botdichtheid. Wij concluderen hieruit dat de mechanische invloed van spieren op 
bot het best voorspeld worden door de absolute spiermassa.
Sarcopenie als voorspeller van balans
In Hoofdstuk acht vergelijken wij de diagnostische criteria voor sarcopenie als 
voorspeller van positionele balans in patiënten van een geriatrische polikliniek. 
Oudere polipatiënten met een hogere spierkracht hadden een betere positionele 
balans dan patiënten met een lagere spierkracht. Spiermassa was een minder goede 




In Hoofdstuk negen wordt een reflectie gegeven op de belangrijkste bevindingen 
van dit proefschrift. Uit dit proefschrift blijkt dat het van belang is onderscheid te 
maken tussen een lage spiermassa en een lage spierkracht op oudere leeftijd. De 
term sarcopenie kan het beste gebruikt worden voor een lage spiermassa, en voor 
een lage spierkracht het woord ‘dynapenie’ gebruikt. 
Kritische kanttekeningen kunnen worden geplaatst bij het gebruik van loopsnelheid 
in de definitie van sarcopenie, zoals door verschillende werkgroepen voor 
sarcopenie is voorgesteld (in combinatie met een lage spiermassa of spierkracht) 
(8;9). Loopsnelheid is geen goede voorspeller voor de vele functies van de spier.
Daarnaast is het van belang relatieve en absolute spiermassa van elkaar te 
onderscheiden. Het verschil tussen deze maten is uit te leggen aan de hand van de 
relaties met vetmassa en totaal lichaamsgewicht. Een hoger lichaamsgewicht gaat 
samen met een lagere relatieve spiermassa maar een hogere absolute spiermassa 
(Figuur 2, Hoofdstuk negen)(14). Vetmassa kan de relatie tussen spiermassa en 
spier-gerelateerde uitkomstmaten beïnvloeden, hiermee dient rekening gehouden 
te worden bij het definiëren van sarcopenie. 
Een ander punt van aandacht bij het definiëren van sarcopenie is het kiezen van 
de juiste referentiepopulatie om afkappunten te bepalen waarbij sprake is van 
sarcopenie. Deze afkappunten moeten voorspellend zijn voor uitkomstmaten. Een 
aantal afkappunten wordt momenteel al gebruikt in de literatuur voor het stellen 
van de diagnose sarcopenie (Tabel 1 van Hoofdstuk 2). 
In de klinische praktijk kan het stellen van de diagnose sarcopenie relevant zijn. 
Bijvoorbeeld kan het aanleiding zijn voor training of aanpassing van voeding. 
Trainingsprogramma’s blijken in staat om de spiermassa en spierkracht bij ouderen 
te vergroten, hoewel niet alle studies succesvol zijn. Tevens zijn er aanwijzingen 
dat suppletie van hormonen of voedingssupplementen kunnen bijdragen aan een 
hogere spiermassa. Grotere studies zijn noodzakelijk om hier meer zekerheid over 
te krijgen. Ook kan het meten van de spiermassa inzicht geven in de vitaliteit van 
de patiënt.
Conclusies en toekomstig onderzoek
Het eerste doel van dit proefschrift was om de consequenties van het hanteren van 
verschillende diagnostische criteria voor sarcopenie te onderzoeken. Dit proefschrift 
laat zien dat de criteria voor sarcopenie niet door elkaar gebruikt kunnen worden 
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in de definitie van sarcopenie. Studies gebaseerd op verschillende diagnostische 
criteria kunnen niet met elkaar worden vergeleken.
 Het uiteindelijke doel van dit proefschrift was het vinden van de beste diagnostische 
criteria om sarcopenie te definiëren. Er kunnen aanbevelingen worden gedaan. De 
term sarcopenie dient te worden gereserveerd voor het beschrijven van een lage 
spiermassa. Voor het beschrijven van een lage spierkracht kan de term ‘dynapenie’ 
worden gebruikt. Het is afhankelijk van de gebruikte spier-gerelateerde uitkomstmaat 
welke maat het meest voorspellend is. Sarcopenie is een betere voorspeller voor de rol 
van de spier als intern orgaan, terwijl dynapenie mogelijk beter is om uitkomstmaten 
te voorspellen waarbij de aansturing van de spier door het zenuwstelsel van belang 
is zoals bij de positionele balans.
Dit proefschrift toont aan dat er een belangrijk verschil is tussen relatieve spiermassa 
en absolute spiermassa. Gebaseerd op resultaten in dit proefschrift is het aan te raden 
om relatieve spiermassa te gebruiken als diagnostisch criterium voor sarcopenie.
Toekomstig onderzoek is nodig om te bepalen of er ook een oorzakelijk verband is 
tussen sarcopenie en spier-gerelateerde uitkomstmaten. Verder is het nodig om in 
grote studies te onderzoeken of het verhogen van de spiermassa ook een verbetering 
geeft van uitkomstmaten op korte en op lange termijn. Op gebied van de geriatrische 
oncologie zijn studies nodig om te onderzoeken of het doseren van chemotherapie op 
basis van spiermassa te verkiezen is boven de huidige strategie om chemotherapie te 
doseren op basis van lichaamsoppervlakte. Kennis over betekenisvolle afkappunten 
voor het vaststellen van sarcopenie in de praktijk is nodig om het debat over de beste 
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